<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Smoking cessation for people with chronic obstructive pulmonary disease - van Eerd, EAM - 2016 | Cochrane Library</title> <meta content="Smoking cessation for people with chronic obstructive pulmonary disease - van Eerd, EAM - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010744.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Smoking cessation for people with chronic obstructive pulmonary disease - van Eerd, EAM - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010744.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010744.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Smoking cessation for people with chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Eva AM van Eerd" name="citation_author"/> <meta content="CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre" name="citation_author_institution"/> <meta content="eva.vaneerd@maastrichtuniversity.nl" name="citation_author_email"/> <meta content="Regina M van der Meer" name="citation_author"/> <meta content="Public Health Service of Haaglanden" name="citation_author_institution"/> <meta content="Onno CP van Schayck" name="citation_author"/> <meta content="Maastricht University (CAPHRI)" name="citation_author_institution"/> <meta content="Daniel Kotz" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010744.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/08/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010744.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010744.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010744.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Behavior Therapy [*methods]; Bupropion [therapeutic use]; Combined Modality Therapy [methods]; Nicotine [therapeutic use]; Nicotinic Agonists [*therapeutic use]; *Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Smoking Cessation [*methods]; Varenicline [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010744.pub2&amp;doi=10.1002/14651858.CD010744.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010744\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010744\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010744.pub2",title:"Smoking cessation for people with chronic obstructive pulmonary disease",firstPublishedDate:"Aug 20, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010744.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010744.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010744.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010744.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010744.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010744.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010744.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010744.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010744.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010744.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15526 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010744.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/appendices#CD010744-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/table_n/CD010744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/table_n/CD010744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Smoking cessation for people with chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#CD010744-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Eva AM van Eerd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#CD010744-cr-0003">Regina M van der Meer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#CD010744-cr-0004">Onno CP van Schayck</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information#CD010744-cr-0005">Daniel Kotz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information/en#CD010744-sec-0091">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 August 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010744.pub2">https://doi.org/10.1002/14651858.CD010744.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010744-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010744-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010744-abs-0001" lang="en"> <section id="CD010744-sec-0001"> <h3 class="title" id="CD010744-sec-0001">Background</h3> <p>Smoking cessation is the most important treatment for smokers with chronic obstructive pulmonary disease (COPD), but little is known about the effectiveness of different smoking cessation interventions for this particular group of smokers. </p> </section> <section id="CD010744-sec-0002"> <h3 class="title" id="CD010744-sec-0002">Objectives</h3> <p>To evaluate the effectiveness of behavioural or pharmacological smoking cessation interventions, or both, in smokers with COPD. </p> </section> <section id="CD010744-sec-0003"> <h3 class="title" id="CD010744-sec-0003">Search methods</h3> <p>We searched all records in the Cochrane Airways Group Specialised Register of Trials. In addition to this electronic search, we searched clinical trial registries for planned, ongoing, and unpublished trials. We searched all databases from their inception. We checked the reference lists of all included studies and of other systematic reviews in relevant topic areas. We searched for errata or retractions from eligible trials on PubMed. We conducted our most recent search in March 2016. </p> </section> <section id="CD010744-sec-0004"> <h3 class="title" id="CD010744-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials assessing the effectiveness of any behavioural or pharmacological treatment, or both, in smokers with COPD reporting at least six months of follow‐up abstinence rates. </p> </section> <section id="CD010744-sec-0005"> <h3 class="title" id="CD010744-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted the data and performed the methodological quality assessment for each study. We resolved any disagreements by consensus. </p> </section> <section id="CD010744-sec-0006"> <h3 class="title" id="CD010744-sec-0006">Main results</h3> <p>We included 16 studies (involving 13,123 participants) in this systematic review, two of which were of high quality. These two studies showed that nicotine sublingual tablet and varenicline increased the quit rate over placebo (risk ratio (RR) 2.60 (95% confidence interval (CI) 1.29 to 5.24) and RR 3.34 (95% CI 1.88 to 5.92)). Pooled results of two studies also showed a positive effect of bupropion compared with placebo (RR 2.03 (95% CI 1.26 to 3.28)). When pooling these four studies, we found high‐quality evidence for the effectiveness of pharmacotherapy plus high‐intensity behavioural treatment compared with placebo plus high‐intensity behavioural treatment (RR 2.53 (95% CI 1.83 to 3.50)). Furthermore, we found some evidence that high‐intensity behavioural treatment increased abstinence rates when compared with usual care (RR 25.38 (95% CI 8.03 to 80.22)) or low‐intensity behavioural treatment (RR 2.18 (95% CI 1.05 to 4.49)). Finally, the results showed effectiveness of various combinations of psychosocial and pharmacological interventions. </p> </section> <section id="CD010744-sec-0007"> <h3 class="title" id="CD010744-sec-0007">Authors' conclusions</h3> <p>We found high‐quality evidence in a meta‐analysis including four (1,540 participants) of the 16 included studies that a combination of behavioural treatment and pharmacotherapy is effective in helping smokers with COPD to quit smoking. Furthermore, we conclude that there is no convincing evidence for preferring any particular form of behavioural or pharmacological treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010744-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010744-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010744-abs-0004">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010744-abs-0003" lang="en"> <h3>What is the best way to help people with chronic obstructive pulmonary disease stop smoking? </h3> <p><b>Review question</b> </p> <p>We wanted to find out the best way to help people with chronic obstructive pulmonary disease (COPD) to stop smoking. </p> <p><b>Background</b> </p> <p>Quitting smoking is the most important treatment for smokers with COPD. Treatments to help this group of people stop smoking can be categorised into behavioural support (such as motivational interviewing) and medication (such as nicotine replacement therapy). Although much research exists looking into what works for 'healthy' smokers, less is known about what is most effective for smokers with COPD. </p> <p><b>Study characteristics</b> </p> <p>We looked for studies that included adult men and women who were current smokers and had a diagnosis of COPD. We included studies that assessed the effectiveness of any behavioural support or medication, or both as an aid to quit smoking. We included studies that compared different types of treatment or compared treatment to stop smoking with no treatment or 'usual care'. We only included studies that reported how many people had stopped smoking after at least six months of follow‐up. We carried out the most recent search for studies in March 2016. </p> <p><b>Key results</b> </p> <p>We found high‐quality evidence from a collection of four (1,540 participants) of the total 16 included studies (13,123 participants) in this review. Overall, we found evidence that smokers with COPD who receive a combination of high‐intensity behavioural support and medication are more than twice as likely to quit as people who receive behavioural support alone. We found no clear evidence that one particular form of behavioural support or medication is better than another. It is still unclear whether smokers with COPD are different from smokers without COPD with regard to which treatments work best to help them stop smoking. </p> <p><b>Quality of the evidence</b> </p> <p>We are quite confident in the finding that a combination of behavioural support and medication works better than behavioural support alone. However, we were not able to combine the results of many of the studies because the treatments or the outcomes of the studies were too different from each other. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010744-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-sec-0076">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-sec-0137">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010744-sec-0076"></div> <h3 class="title" id="CD010744-sec-0077">Implications for practice</h3> <section id="CD010744-sec-0077"> <p>Based on four studies involving 1,540 participants, we found high‐quality evidence that a combination of behavioural treatment and pharmacotherapy is effective in helping smokers with COPD quit. Furthermore, we conclude that there is no convincing evidence for preferring any particular form of behavioural or pharmacological treatment. </p> </section> <h3 class="title" id="CD010744-sec-0078">Implications for research</h3> <section id="CD010744-sec-0078"> <p>There is no evidence to change the present international smoking cessation guidelines for smokers with COPD. The question still remains of whether smokers with COPD require a different smoking cessation treatment than smokers without COPD. Although some evidence suggests that smokers with COPD have specific features that make it harder for them to quit (<a href="./references#CD010744-bbs2-0111" title="Jimenez‐RuizCA , AndreasS , LewisKE , TonnesenP , vanSchayckCP , HajekP , et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. European Respiratory Journal2015;46(1):61‐79. [PUBMED: 25882805] ">Jimenez‐Ruiz 2015</a>; <a href="./references#CD010744-bbs2-0130" title="vanEerdEA , vanRossemCR , SpigtMG , WesselingG , vanSchayckOC , KotzD . Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco‐smoking. Respiration2015 (published online); Vol. 90, issue 3:211‐9. ">van Eerd 2015</a>), more research in this field is needed. Future research on smoking cessation interventions for smokers with COPD could then focus on investigating which behavioural‐change techniques specifically motivate people with COPD to quit, and which could be added to existing interventions, such as symptom diaries or exercise capacity testing. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010744-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010744-sec-0015"></div> <div class="table" id="CD010744-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Behavioural treatment compared to no treatment or usual care in smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Behavioural treatment compared to no treatment or usual care in smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> in‐ and outpatients<br/> <b>Intervention:</b> behavioural treatment<br/> <b>Comparison:</b> no treatment or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No treatment or usual care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Behavioural treatment </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><br/> (14 to 138) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 25.38 (95% CI 8.03, 80.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3562<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 12 to 48 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3618<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to clinical and statistical heterogeneity, studies were not pooled. Individual RR were 1.98 (95% CI 0.74, 5.31) and RR 9.33 (95% CI 7.26, 11.99). 1 study had a high risk of bias due to a serious risk of contamination bias </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>This study had an unclear risk of bias as several important items were scored unclear, for example random sequence generation and allocation concealment. Downgrade once. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010744-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> in‐ and outpatients<br/> <b>Intervention:</b> one form of behavioural treatment<br/> <b>Comparison:</b> a different form of behavioural treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>A different form of behavioural treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>One form of behavioural treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>739<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. Individual RR were 2.18 (1.05, 4.49), RR 0.97 (0.47, 1.99), RR 1.09 (0.59, 2.04), and RR not estimable. 3 of the 4 studies had a low risk of bias. 1 study had a high risk of bias due to poor adherence to the study protocol </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. Individual RR were 1.67 (0.68, 4.11), RR 1.35 (0.80, 2.28), and RR 0.15 (0.01, 2.83). 1 study had a low risk of bias, 1 study had a high risk of bias due to participants' poor adherence to the study protocol, and the remaining study had an unclear risk of bias </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD010744-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pharmacological treatment compared to placebo in smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment compared to placebo in smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> pharmacological treatment<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pharmacological treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b><br/> (136 to 207) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.53 (95% CI 1.83, 3.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months RR 2.54 (95% CI 0.87, 7.44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; nicotine replacement therapy</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b><br/> (70 to 283) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.60 (95% CI 1.29, 5.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up; nicotine replacement therapy</b> <br/> Follow‐up: 12 months RR 1.78 (95% CI 1.04, 3.05) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; bupropion</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><br/> (110 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.03 (95% CI 1.26, 3.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up; bupropion</b><br/> Follow‐up: 6 months RR 1.46 (95% CI 0.97, 2.19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; varenicline</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (104 to 326) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.34 (95% CI 1.88, 5.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up; varenicline</b><br/> Follow‐up: 12 months RR 1.83 (95% CI 1.27, 2.65) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; nortriptyline</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b><br/> (72 to 620) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 0.87, 7.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No point prevalence data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Three studies had a low risk of bias. One study had a high risk of bias due to poor adherence to the study protocol. No downgrade.<br/> <sup>2</sup>Sensitivity analyses including only those studies judged to be at low risk of bias did not impact the pooled results. No downgrade.<br/> <sup>3</sup>One study had a low risk of bias. One study had a high risk of bias due to poor adherence to the study protocol. Downgrade once.<br/> <sup>4</sup>This study had a high risk of bias due to poor adherence to the study protocol. Downgrade once. </p> <p><sup>5</sup>Point estimate for prolonged abstinence includes no difference. Downgrade once for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010744-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> pharmacological treatment<br/> <b>Comparison:</b> a different pharmacological treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>A different pharmacological treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pharmacological treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. NRT vs bupropion RR 0.74 (95% CI 0.27, 2.05), bupropion vs nortriptyline RR 1.29 (95% CI 0.63, 2.63). 1 study had a high risk of bias due to poor adherence to the study protocol. 1 study had an unclear risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b><br/> (91 to 264) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.5<br/> (1.47 to 4.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NRT vs NRT plus bupropion</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>NRT:</b> nicotine replacement therapy <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>This study had a high risk of bias due to contamination bias. Downgrade once. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010744-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Combination interventions compared to different (combination) interventions or usual care for smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combination interventions compared to different (combination) interventions or usual care for smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> in‐ and outpatients<br/> <b>Intervention:</b> combination interventions<br/> <b>Comparison:</b> different (combination) interventions or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Different (combination) interventions or usual care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Combination interventions</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 60 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6431<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. Individual RR 4.10 (3.36, 5.00), RR 2.22 (1.06, 4.68), RR 1.91 (0.65, 5.61), and RR not estimable. 3 studies had a low risk of bias, 1 study had a high risk of bias due to poor adherence to the study protocol </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1535<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling. Individual RR were 1.60 (0.89, 2.89), RR 2.21 (0.89, 5.52), RR 3.41 (2.15, 5.41), RR 0.43 (0.02, 10.12), and RR 3.62 (0.40, 32.97). 3 studies had a high risk of bias due to contamination bias, poor adherence to the study protocol, or poor validation of outcome. 1 study had a low risk of bias </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010744-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-sec-0016">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-sec-0100">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD010744-sec-0016"></div> <section id="CD010744-sec-0017"> <h3 class="title" id="CD010744-sec-0017">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD), a common and largely preventable disease, is characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response to noxious particles in the airways and the lung (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). Exacerbations and comorbidities contribute to the overall severity in individual patients. The diagnosis must be confirmed by spirometry, the most widely available reproducible test of lung function (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). </p> <p>COPD prevalence, morbidity, and mortality vary across countries and across different groups within countries (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). For example, a worldwide study showed that the prevalence of moderate COPD (that is Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II) in women 40 years of age or older ranged from 3.1% to 12.6%, and in men from 6.7% to 13.1% (<a href="./references#CD010744-bbs2-0094" title="BuistAS , McBurnieMA , VollmerWM , GillespieS , BurneyP , ManninoDM , et al. International variation in the prevalence of COPD (the BOLD study): a population‐based prevalence study. The Lancet2007; Vol. 370, issue 9589:741‐50. ">Buist 2007</a>). This variation in prevalence is partly due to differences in pack‐years of smoking history. The odds ratio of COPD per 10‐year interval of pack‐years of smoking is 1.28 (95% confidence interval (CI) 1.15 to 1.42) among women and 1.16 (95% CI 1.12 to 1.21) among men (<a href="./references#CD010744-bbs2-0094" title="BuistAS , McBurnieMA , VollmerWM , GillespieS , BurneyP , ManninoDM , et al. International variation in the prevalence of COPD (the BOLD study): a population‐based prevalence study. The Lancet2007; Vol. 370, issue 9589:741‐50. ">Buist 2007</a>). Except for differences in exposure to risk factors, COPD prevalence variation is due to differences in diagnostic criteria, survey methods, and analytical approaches. Under‐recognition and underdiagnosis of COPD also affects the accuracy of prevalence and mortality data. In a large‐scale English study, the prevalence of COPD was highest among current smokers (19.3%), followed by ex‐smokers (15.2%) and never smokers (8.2%) (<a href="./references#CD010744-bbs2-0121" title="ShahabL , JarvisMJ , BrittonJ , WestR . Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax2006;61(12):1043‐7. ">Shahab 2006</a>). Furthermore, the prevalence of undetected COPD was high among asymptomatic smokers. The prevalence of previously undiagnosed COPD in male smokers 40 years of age or older ranged from 12% in a Greek research population, in <a href="./references#CD010744-bbs2-0128" title="TzanakisN , AnagnostopoulouU , FiladitakiV , ChristakiP , SiafakasN . Prevalence of COPD in Greece. Chest2004;125(3):892‐900. ">Tzanakis 2004</a>, to 30% in a Dutch research population (<a href="./references#CD010744-bbs2-0099" title="GeijerRM , SachsAP , HoesAW , SalomePL , LammersJW , VerheijTJ . Prevalence of undetected persistent airflow obstruction in male smokers 40‐65 years old. Family Practice2005;22(5):485‐9. ">Geijer 2005</a>). The Global Burden of Disease Study projected that COPD will become the third‐leading cause of death worldwide by 2020 (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). This increased mortality is driven mainly by the expanding epidemic of tobacco smoking, reduced mortality from other common causes of death, and aging of the world population (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). </p> <p>The risk for developing COPD results from an interaction between genetic factors and many different environmental exposures (<a href="./references#CD010744-bbs2-0115" title="ManninoDM , BuistAS . Global burden of COPD: risk factors, prevalence, and future trends. The Lancet2007;370(9589):765‐73. ">Mannino 2007</a>). Cigarette smoking is the most commonly encountered risk factor for COPD in high‐income countries (<a href="./references#CD010744-bbs2-0096" title="CelliBR , MacNeeW . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal2004;23(6):932‐46. ">Celli 2004</a>; <a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>; <a href="./references#CD010744-bbs2-0113" title="KohansalR , Martinez‐CamblorP , AgustiA , BuistAS , ManninoDM , SorianoJB . The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. American Journal of Respiratory and Critical Care Medicine2009;180(1):3‐10. ">Kohansal 2009</a>). Furthermore, a higher prevalence of respiratory symptoms and lung function abnormalities and a higher COPD mortality rate are seen among cigarette smokers with COPD than non‐smokers with COPD (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). For example, an overview of the literature showed the effect of smoking on forced expiratory volume in one second (FEV1) in males with mild to moderate COPD (<a href="./references#CD010744-bbs2-0135" title="WillemseBW , PostmaDS , TimensW , tenHackenNH . The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. European Respiratory Journal2004;23(3):464‐76. ">Willemse 2004</a>). The FEV1 of participants who continued to smoke declined within a range of 42 to 82 mL per year compared with 0 to 49 mL per year in participants who quit smoking at the start of the study (<a href="./references#CD010744-bbs2-0135" title="WillemseBW , PostmaDS , TimensW , tenHackenNH . The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. European Respiratory Journal2004;23(3):464‐76. ">Willemse 2004</a>). The latter decline is comparable with the physiological lung function decline that occurs naturally with increasing age (<a href="./references#CD010744-bbs2-0112" title="KerstjensHA , RijckenB , SchoutenJP , PostmaDS . Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax1997;52(9):820‐7. ">Kerstjens 1997</a>). </p> <p>Smoking cessation is the only evidence‐based intervention that reduces the risk of developing COPD and slows the accelerated decline in lung function in people with COPD (<a href="./references#CD010744-bbs2-0092" title="AnthonisenNR , ConnettJE , MurrayRP . Smoking and lung function of lung health study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675‐9. ">Anthonisen 2002</a>). To date, none of the existing medications for COPD have been conclusively shown to modify the long‐term decline in lung function (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). Furthermore, smoking cessation is the single most cost‐effective way to reduce the risk of development of COPD and worsening of the disease (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>). </p> </section> <section id="CD010744-sec-0018"> <h3 class="title" id="CD010744-sec-0018">Description of the intervention</h3> <p>For the current review, we included randomised controlled trials that assessed the effectiveness of any form of behavioural or pharmacological treatment, or combinations of both, as an aid to smoking cessation in people with COPD. Behavioural treatment refers to any psychotherapeutic approach aimed at identifying and modifying the behaviours associated with smoking (<a href="./references#CD010744-bbs2-0126" title="TobaccoUse , Dependence GuidelinePanel . Treating tobacco use and dependence: 2008 update. www.ncbi.nlm.nih.gov/books/NBK63950/ (accessed 5 December 2012). ">Tobacco Use and Dependence Guideline Panel 2008</a>). Pharmacological treatments included nicotine replacement therapy (NRT), antidepressants for smoking cessation, nicotine receptor partial agonists, and nicotine vaccines. The following NRT delivery systems are currently available: nicotine chewing gum, nicotine inhaler, nicotine lozenge, nicotine patch, and nicotine sprays. Bupropion is the most commonly used antidepressant, as nortriptyline is not registered as a smoking cessation aid and is rarely used now. Varenicline is the most commonly used nicotine receptor partial agonist. Vaccines are not currently licensed for public use, although several vaccines are under development. A smoking cessation intervention is often a combination of a pharmacological and a behavioural treatment. </p> </section> <section id="CD010744-sec-0019"> <h3 class="title" id="CD010744-sec-0019">How the intervention might work</h3> <p>Smoking is an addictive behaviour. The chances of successful smoking cessation are therefore reduced without the use of behavioural or pharmacological treatments, or both. In the general smoking population, several behavioural and pharmacological treatments have demonstrated efficacy in helping to achieve abstinence. For example, the antidepressants nortriptyline and bupropion aid long‐term smoking cessation, and evidence suggests that the mode of action is independent of their antidepressant effects (<a href="./references#CD010744-bbs2-0108" title="HughesJR . Use of nicotine replacement after a smoking lapse. Nicotine and Tobacco Research2012;14(6):751‐4. ">Hughes 2012</a>). Their efficacy is similar to that of NRT (<a href="./references#CD010744-bbs2-0109" title="HughesJR , SteadLF , Hartmann‐BoyceJ , CahillK , LancasterT . Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD000031.pub4; PUBMED: 24402784] ">Hughes 2014</a>). A review of nicotine receptor partial agonists showed that varenicline increased the chances of successful long‐term smoking cessation compared with bupropion (<a href="./references#CD010744-bbs2-0095" title="CahillK , StevensS , PereraR , LancasterT . Pharmacological interventions for smoking cessation: an overview and network meta‐analysis. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD009329.pub2; PUBMED: 23728690] ">Cahill 2013</a>). Comparison of NRT and varenicline suggested a minor benefit of varenicline tending towards equivalency (<a href="./references#CD010744-bbs2-0095" title="CahillK , StevensS , PereraR , LancasterT . Pharmacological interventions for smoking cessation: an overview and network meta‐analysis. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD009329.pub2; PUBMED: 23728690] ">Cahill 2013</a>). Furthermore, a recent review showed the nicotine receptor partial agonist cytisine to be an effective treatment for smoking cessation (<a href="./references#CD010744-bbs2-0103" title="HajekP , McRobbieH , MyersK . Efficacy of cytisine in helping smokers quit: systematic review and meta‐analysis. Thorax2013; Vol. 68, issue 11:1037‐42. [DOI: 10.1136/thoraxjnl‐2012‐203035] ">Hajek 2013</a>). Interventions that combine behavioural and pharmacological treatments are even more successful in achieving abstinence (<a href="./references#CD010744-bbs2-0122" title="SteadLF , KoilpillaiP , LancasterT . Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD009670.pub3; PUBMED: 26457723] ">Stead 2015</a>). Providing behavioural treatment in person or via telephone for people using pharmacotherapy to stop smoking showed a small but important effect (<a href="./references#CD010744-bbs2-0122" title="SteadLF , KoilpillaiP , LancasterT . Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD009670.pub3; PUBMED: 26457723] ">Stead 2015</a>). However, these studies did not make a distinction between different kinds of smokers, even though there is some evidence that smokers with COPD are different from smokers without COPD. <a href="./references#CD010744-bbs2-0110" title="Jimenez‐RuizCA , MasaF , MiravitllesM , GabrielR , ViejoJL , VillasanteC , et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest2001;119(5):1365‐70. ">Jimenez‐Ruiz 2001</a> showed that smokers with COPD have more pack‐years of smoking history, stronger dependence on cigarettes, and use particular inhalation patterns while smoking. Furthermore, findings of a recent study endorsed the higher cigarette dependence in smokers with COPD and suggested that smokers with COPD have higher levels of depression and lower self efficacy to refrain from smoking (<a href="./references#CD010744-bbs2-0130" title="vanEerdEA , vanRossemCR , SpigtMG , WesselingG , vanSchayckOC , KotzD . Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco‐smoking. Respiration2015 (published online); Vol. 90, issue 3:211‐9. ">van Eerd 2015</a>). This suggests that smokers are not a homogeneous group. It is therefore important to make the intervention fit best for each specific group, such as people with COPD (<a href="./references#CD010744-bbs2-0093" title="BorrelliB , HayesRB , DunsigerS , FavaJL . Risk perception and smoking behavior in medically ill smokers: a prospective study. Addiction2010;105(6):1100‐8. ">Borrelli 2010</a>), for example by giving valuable and clear information on how smoking is related to COPD and to respiratory symptoms. It might also be useful to specifically address the increased comorbidities and cigarette dependence levels reported in people with COPD. </p> </section> <section id="CD010744-sec-0020"> <h3 class="title" id="CD010744-sec-0020">Why it is important to do this review</h3> <p>Smoking cessation is the most important intervention to reduce the risk of developing COPD and to improve the prognosis of people with the disease. People with COPD have a more urgent need to stop smoking than the average smoker; moreover, many often find it more difficult to do so (<a href="./references#CD010744-bbs2-0127" title="TonnesenP , CarrozziL , FagerstromKO , GratziouC , Jimenez‐RuizC , NardiniS , et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. European Respiratory Journal2007;29(2):390‐417. ">Tonnesen 2007</a>). It is therefore important to provide an overview of the evidence base for different smoking cessation interventions directed at these patients. </p> <p>Compared with smokers from the general population, smokers with COPD might have more difficulty quitting smoking because of their higher number of pack‐years of smoking history, stronger dependence on nicotine, higher levels of depression, and a lower self efficacy to refrain from smoking (<a href="./references#CD010744-bbs2-0110" title="Jimenez‐RuizCA , MasaF , MiravitllesM , GabrielR , ViejoJL , VillasanteC , et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest2001;119(5):1365‐70. ">Jimenez‐Ruiz 2001</a>; <a href="./references#CD010744-bbs2-0121" title="ShahabL , JarvisMJ , BrittonJ , WestR . Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax2006;61(12):1043‐7. ">Shahab 2006</a>; <a href="./references#CD010744-bbs2-0130" title="vanEerdEA , vanRossemCR , SpigtMG , WesselingG , vanSchayckOC , KotzD . Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco‐smoking. Respiration2015 (published online); Vol. 90, issue 3:211‐9. ">van Eerd 2015</a>). A Dutch study showed that smokers with mild to severe COPD were less likely to achieve abstinence than smokers without COPD; the prolonged abstinence rate after six months with nortriptyline therapy was 21% in smokers with COPD compared with 32% in smokers without COPD (<a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>). However, that study did not control for baseline differences. Interventions aimed at smokers with COPD therefore might need to be tailored more specifically to the needs of people with COPD to increase their desire to stop and to address their increased levels of nicotine dependence and depression and their lower self efficacy (<a href="./references#CD010744-bbs2-0121" title="ShahabL , JarvisMJ , BrittonJ , WestR . Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax2006;61(12):1043‐7. ">Shahab 2006</a>; <a href="./references#CD010744-bbs2-0130" title="vanEerdEA , vanRossemCR , SpigtMG , WesselingG , vanSchayckOC , KotzD . Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco‐smoking. Respiration2015 (published online); Vol. 90, issue 3:211‐9. ">van Eerd 2015</a>). However, evidence for the effectiveness of tailored versus general smoking cessation interventions in this patient group is scarce. </p> <p>The scope of this updated review was the same as the original Cochrane review: to review the evidence 'whether and which treatments are effective in COPD smokers' (<a href="./references#CD010744-bbs2-0137" title="van derMeerRM , WagenaEJ , OsteloRW , JacobsJE , vanSchayckCP . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2003, Issue 8. [DOI: 10.1002/14651858.CD002999; PUBMED: 12804448] ">van der Meer 2003</a>). However, results may have changed because new trials on this subject have been published since 2003. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010744-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-sec-0021">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-sec-0105">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010744-sec-0021"></div> <p>To evaluate the effectiveness of behavioural or pharmacological smoking cessation interventions, or both, in smokers with COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010744-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-sec-0022">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-sec-0106">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010744-sec-0022"></div> <section id="CD010744-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010744-sec-0024"> <h4 class="title">Types of studies</h4> <p>We examined randomised controlled trials.</p> </section> <section id="CD010744-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included smokers with a diagnosis of COPD, according to criteria from the guidelines of the American Thoracic Society (ATS) (<a href="./references#CD010744-bbs2-0119" title="QaseemA , WiltTJ , WeinbergerSE , HananiaNA , CrinerG , van derMolenT , et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155(3):179‐91. ">Qaseem 2011</a>), the British Thoracic Society (BTS) (<a href="./references#CD010744-bbs2-0117" title="NICE . Chronic obstructive pulmonary disease in over 16s: diagnosis and management (CG101). www.nice.org.uk/CG101 (accessed 30 June 2016). ">NICE 2010</a>), or GOLD (<a href="./references#CD010744-bbs2-0100" title="Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. www.goldcopd.org/guidelines‐global‐strategy‐for‐diagnosis‐management.html (accessed 17 November 2015). ">GOLD 2015</a>), or as confirmed by the treating physician. </p> </section> <section id="CD010744-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included randomised controlled trials that assessed the effectiveness of any behavioural or pharmacological treatment, or both, as an aid to smoking cessation in participants with COPD. We categorised behavioural treatment as 'high' if more than one pre‐scheduled counselling session of greater than 10 minutes was offered with at least one face‐to‐face counselling session (<a href="./references#CD010744-bbs2-0098" title="US Department of Health and Human Services. Public Health Service. Clinical practice guideline. Treating tobacco use and dependence: 2008 update. www.ncbi.nlm.nih.gov/books/NBK63952/ (accessed 17 November 2015). ">Fiore 2008</a>). Otherwise we categorised the behavioural treatment as 'low'. </p> <p>We included the following comparisons.</p> <p> <ul id="CD010744-list-0001"> <li> <p>Behavioural treatment versus no treatment or usual care.</p> </li> <li> <p>One form of behavioural treatment versus a different form of behavioural treatment.</p> </li> <li> <p>Pharmacological treatment versus placebo.</p> </li> <li> <p>Pharmacological treatment versus a different pharmacological treatment.</p> </li> <li> <p>Comparison of different combinations of behavioural and pharmacological treatments.</p> </li> </ul> </p> </section> <section id="CD010744-sec-0027"> <h4 class="title">Types of outcome measures</h4> <p>As the primary outcome, we were interested in the percentage of participants who met the criteria for 'continuous or prolonged abstinence' over a period of six months or longer. 'Continuous abstinence' refers to abstinence periods that begin on the quit date. 'Prolonged abstinence' refers to continuous abstinence after an initial 'grace period' (<a href="./references#CD010744-bbs2-0107" title="HughesJR , KeelyJP , NiauraRS , Ossip‐KleinDJ , RichmondRL , SwanGE . Measures of abstinence in clinical trials: issues and recommendations. Nicotine and Tobacco Research2003;5(1):13‐25. ">Hughes 2003</a>). The preferred outcome was biochemically validated continuous or prolonged abstinence at the longest‐reported time point. However, as biochemically validated abstinence might be lacking, we examined both self reported abstinence and biochemically validated abstinence. Unfortunately, lack of clarity is evident in the literature about the reliability of self reported abstinence (<a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0136" title="WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. ">Wilson 2011</a>). When it was unclear whether the given quit rate was a point prevalence or a continuous or prolonged abstinence rate, we defined the quit rate as point prevalence. 'Point prevalence abstinence rate' refers to the proportion of participants who were non‐smokers at a specific point in time during follow‐up. It is a considerably less valid estimate of smoking abstinence than continuous/prolonged abstinence because participants could be classified as non‐smokers even if they had smoked a week before the reference date (<a href="./references#CD010744-bbs2-0123" title="StrassmannR , BauschB , SpaarA , KleijnenJ , BraendliO , PuhanMA . Smoking cessation interventions in COPD: a network meta‐analysis of randomised trials. European Respiratory Journal2009;34(3):634‐40. ">Strassmann 2009</a>; <a href="./references#CD010744-bbs2-0134" title="WestR , HajekP , SteadL , StapletonJ . Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction2005;100(3):299‐303. [PUBMED: 15733243] ">West 2005</a>). We therefore used continuous or prolonged abstinence as the primary outcome measure, and point prevalence as the secondary outcome measure. </p> <section id="CD010744-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010744-list-0002"> <li> <p>Percentage of participants with continuous or prolonged abstinence over a period of six months or longer. </p> </li> </ul> </p> </section> <section id="CD010744-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010744-list-0003"> <li> <p>Percentage of participants with point prevalence abstinence over a period of six months or longer. </p> </li> </ul> </p> </section> </section> </section> <section id="CD010744-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010744-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register of Trials (CAGR), which is derived from systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO (please see <a href="./appendices#CD010744-sec-0082">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy described in <a href="./appendices#CD010744-sec-0088">Appendix 2</a>. In addition to the electronic search, we searched clinical trial registries for planned, ongoing, and unpublished trials (for example ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform). We searched all databases from their inception to March 2016, and applied no restriction on language of publication. </p> </section> <section id="CD010744-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all included studies and other systematic reviews in relevant topic areas. We searched for errata or retractions from eligible trials in PubMed on 22 March 2016. </p> </section> </section> <section id="CD010744-sec-0033"> <h3 class="title" id="CD010744-sec-0033">Data collection and analysis</h3> <section id="CD010744-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EVE and RVDM) independently selected studies for inclusion by applying the selection criteria. We resolved any disagreements through discussion, consulting a third review author (DK) if required. We identified and excluded duplicates and collated multiple reports on the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) flow diagram and a <a href="./references#CD010744-sec-0098" title="">Characteristics of excluded studies</a> table (<a href="./references#CD010744-bbs2-0114" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology2009;62(10):e1‐34. ">Liberati 2009</a>). </p> </section> <section id="CD010744-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (EVE and RVDM) independently extracted study characteristics from included studies. We adapted the standard data collection form for study characteristics and outcome data to the inclusion criteria. We noted in the <a href="./references#CD010744-sec-0097" title="">Characteristics of included studies</a> table whether outcome data were reported in an unuseable way. One review author (EVE) copied the data from the data collection form into the <a href="./references#CD010744-bbs2-0120" title="The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen. Review Manager (RevMan). Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014. ">RevMan 2014</a> file. We double‐checked that the data had been entered correctly by comparing the study reports with the presentation of data in the systematic review. We extracted the following study characteristics. </p> <p> <ul id="CD010744-list-0004"> <li> <p>Methods: study setting, study design, method of recruitment of participants, number of participants randomly assigned and followed up. </p> </li> <li> <p>Participants: age, sex, cigarettes smoked per day, mean score on Fagerström Test for Nicotine Dependence (FTND) (<a href="./references#CD010744-bbs2-0105" title="HeathertonTF , KozlowskiLT , FreckerRC , FagerstromKO . The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction1991;86(9):1119‐27. [PUBMED: 1932883] ">Heatherton 1991</a>), severity of COPD baseline lung function (FEV1 and forced vital capacity (FVC)). </p> </li> <li> <p>Interventions: description of the experimental and control group(s), type and intensity of the behavioural treatment, therapist providing the treatment, dose of the pharmacological treatment. </p> </li> <li> <p>Outcomes: primary and secondary outcomes, respectively, percentage of participants with prolonged or continuous abstinence, or both; percentage of participants with point prevalence abstinence; biochemical validation of abstinence. </p> </li> <li> <p>Statistical analyses: complete‐case analyses or imputation of outcome data.</p> </li> <li> <p>Notes: funding for trial, notable conflicts of interest of trial authors.</p> </li> </ul> </p> </section> <section id="CD010744-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (EVE and RVDM) independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010744-bbs2-0106" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley &amp; Sons, 2008. ">Higgins 2011</a>). We resolved any disagreements by discussion or by involving a third review author (DK). We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD010744-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of the outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low, or unclear and provided a quote from the study report, together with a justification for our judgement, in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. When information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <section id="CD010744-sec-0037"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD010744-sec-0095">Differences between protocol and review</a> section (<a href="./references#CD010744-bbs2-0129" title="vanEerdEAM , van derMeerRM , RedaAA , vanSchayckCP , KotzD . Smoking cessation in smokers with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 9. [DOI: 10.1002/14651858.CD010744] ">van Eerd 2013</a>). </p> </section> </section> <section id="CD010744-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed results for dichotomous outcomes as risk ratios (RRs) and risk difference (RD). We calculated RRs as follows: (number of participants who quit smoking in the intervention group/number of participants randomly assigned to the intervention group)/(number of participants who quit smoking in the control group/number of participants randomly assigned to the control group). An RR greater than one favours the intervention group. RDs were the differences between the observed risks of abstinence in the intervention groups and the observed risks of abstinence in the control groups. We furthermore calculated 95% confidence interval for every study. </p> <p>We undertook meta‐analyses only when this was meaningful, for example if interventions, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>When multiple trial arms were reported in a single trial, we included only the relevant arms. If two comparisons (for example drug A versus placebo and drug B versus placebo) had to be entered into the same meta‐analysis, we combined the intervention groups into one comparison to avoid double counting. </p> </section> <section id="CD010744-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant.</p> </section> <section id="CD010744-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators to verify key study characteristics and to obtain missing numerical outcome data when possible (for example when a study is identified as abstract only). </p> <p>Furthermore, regarding smoking cessation, we considered participants with missing outcome data as smokers (intention to treat). </p> </section> <section id="CD010744-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. The I² statistic describes the percentage of variability in the summary estimate due to systematic heterogeneity rather than random chance stemming from sample error alone (<a href="./references#CD010744-bbs2-0106" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley &amp; Sons, 2008. ">Higgins 2011</a>). Values greater than 50% suggest moderate heterogeneity, and values greater than 75% suggest substantial heterogeneity. When we identified substantial heterogeneity, we explored this through prespecified subgroup analysis. </p> </section> <section id="CD010744-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>When we suspected reporting bias, we attempted to contact study authors to ask them to provide missing outcome data. When this was not possible, and the missing data were thought to introduce serious bias, we explored the impact of including such studies in the overall assessment of results by a sensitivity analysis<b>.</b> </p> <p>When we were able to pool more than 10 trials, we created and examined a funnel plot to explore possible publication biases. </p> </section> <section id="CD010744-sec-0043"> <h4 class="title">Data synthesis</h4> <section id="CD010744-sec-0044"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table by using the following outcomes: the primary outcome percentage of participants with prolonged or continuous abstinence, or both, and the secondary outcome percentage of participants with point prevalence abstinence<i>.</i> We used the five Grades of Recommendation, Assessment, Development and Evaluation (GRADE) considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD010744-bbs2-0102" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924‐6. ">Guyatt 2008</a>). We used methods and recommendations as described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010744-bbs2-0106" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley &amp; Sons, 2008. ">Higgins 2011</a>), and as used in <a href="./references#CD010744-bbs2-0101" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 30 June 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT</a> software. We justified all decisions to downgrade or upgrade the quality of studies by using footnotes and making comments to aid the reader's understanding of the review when necessary. </p> </section> </section> <section id="CD010744-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To examine whether the intervention effect varies in different subgroups, we planned to carry out the following subgroup analyses, when applicable. </p> <p> <ul id="CD010744-list-0006"> <li> <p>Severity of COPD: mild‐moderate versus severe‐very severe.</p> </li> <li> <p>Level of behavioural treatment: low versus high.</p> </li> <li> <p>Type of pharmacotherapy: nicotine replacement therapy, nicotine receptor partial agonists, antidepressants, nicotine vaccines. </p> </li> <li> <p>Definition of abstinence: percentage of participants with continuous or prolonged abstinence over a period of 12 months or longer versus less than 12 months versus percentage of participants with point prevalence. </p> </li> </ul> </p> <p>We used the following outcomes in the subgroup analysis.</p> <p> <ul id="CD010744-list-0007"> <li> <p>Smoking status (% of group) at a minimum of six months from the quit date.</p> </li> </ul> </p> </section> <section id="CD010744-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses to assess the effect of removing studies with a high risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010744-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010744-sec-0047"></div> <section id="CD010744-sec-0048"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD010744-sec-0097" title="">Characteristics of included studies</a> tables. </p> <section id="CD010744-sec-0049"> <h4 class="title">Results of the search</h4> <p>We completed a PRISMA flow diagram (<a href="./references#CD010744-bbs2-0114" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology2009;62(10):e1‐34. ">Liberati 2009</a>; <a href="#CD010744-fig-0001">Figure 1</a>). We identified 390 records by searching the Cochrane Airways Group Specialised Register of Trials, and additional sources added 20 records. Based on title and abstract, we excluded 287 records and assessed 119 full‐text articles for eligibility. We included a total of 16 studies in the review (<a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a>; <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a>; <a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a>; <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>; <a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>; <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>; <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a>; <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a>; <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a>; <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>; <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>; <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>). Five of these were also included in the previous version of this Cochrane review (<a href="./references#CD010744-bbs2-0137" title="van derMeerRM , WagenaEJ , OsteloRW , JacobsJE , vanSchayckCP . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2003, Issue 8. [DOI: 10.1002/14651858.CD002999; PUBMED: 12804448] ">van der Meer 2003</a>). Of the 16 studies, four reported their data in two publications: <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a> and Kallan 1997, <a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a> and Christenhusz 2011, <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> and Hilberink 2005, and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> and Van Schayck 2009. Two studies reported their data in three publications: <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>, <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>b, and Lock 2011; and <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>, Wilson 2010, and <a href="./references#CD010744-bbs2-0136" title="WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. ">Wilson 2011</a>. One study reported results in four publications: <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>, Kotz 2007, <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>b, and <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>c. One study reported the results in several different articles, of which we used five: <a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a>, Connett 1993, O'Hara 1993, Buist 1997, and Scanlon 2000. </p> <div class="figure" id="CD010744-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram" data-id="CD010744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> </div> </section> <section id="CD010744-sec-0050"> <h4 class="title">Included studies</h4> <p>We included 16 studies in this review update involving a total of 13,123 participants. An overview of the included studies is described in <a href="#CD010744-tbl-0006">Table 1</a>, and the key characteristics of the studies are described in detail in the <a href="./references#CD010744-sec-0097" title="">Characteristics of included studies</a> table. </p> <div class="table" id="CD010744-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting (in‐/outpatients)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N completed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control 2</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA &amp; US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5887</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In &amp; out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NOR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NOR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3562</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2607</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐VAR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NOR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CA: Canada; CN: China; DK: Denmark; IE: Ireland; NL: Netherlands; PL: Poland; SE: Sweden; US: United States </p> <p>BH: behavioural; BUP: bupropion; NA: not applicable; NOR: nortriptyline; NRT: nicotine replacement therapy; PH: pharmacological; UC: usual care; VAR: varenicline </p> </div> </div> <section id="CD010744-sec-0051"> <h5 class="title">Study participants</h5> <p>All participants were smokers with a diagnosis of COPD. All studies carried out spirometry to confirm the diagnosis of COPD, except for three studies that did not confirm the COPD diagnosis by spirometry (<a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a>). Half of the studies included an equal distribution of men and women (<a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>; <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a>; <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>; <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>); in the other half of the studies the percentage of men exceeded the percentage of women. The age of the participants in the different studies ranged from 48 to 66 years. Four studies included participants visiting inpatient clinics (<a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a>; <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>; <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a>), whereas the remaining studies included participants visiting outpatient clinics or practices. Eight of the studies described severity of COPD according to Global Initiative for Chronic Obstructive Lung Disease/National Institute for Health and Care Excellence/European Respiratory Society/American Thoracic Society guidelines. One study, <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>, described severity of COPD according to their own definitions: early COPD (FEV1 70% to 90%) and late COPD (FEV1 less than 70%). <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a> and <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> included only participants classified with mild‐moderate COPD; the other six studies included a mix of mild‐moderate and severe‐very severe COPD participants. Four studies included mostly participants with mild‐moderate COPD, and two, <a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a> and <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>, included a large group of severe‐very severe COPD participants. In <a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a>, 57% of COPD participants had mild‐moderate COPD, and 43% had severe‐very severe COPD. In <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>, 62% had mild‐moderate COPD, and 38% had severe‐very severe COPD. </p> </section> <section id="CD010744-sec-0052"> <h5 class="title">Interventions</h5> <p>Eight studies evaluated behavioural treatments, in some of which pharmacotherapy was recommended or obligatory. Six studies evaluated pharmacotherapy, all of which included mandatory behavioural treatment. Five studies evaluated different combinations of behavioural and pharmacological treatment. </p> <section id="CD010744-sec-0053"> <h6 class="title">Behavioural treatments</h6> <p>The content of the behavioural treatments varied widely. All behavioural treatments contained some form of individual counselling, often combined with some form of group counselling, telephone counselling, and/or self help/written material. All of the behavioural treatments except for one, <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>, were high‐intensity treatments because they offered more than one pre‐scheduled counselling session of greater than 10 minutes with at least one face‐to‐face counselling session (<a href="./references#CD010744-bbs2-0098" title="US Department of Health and Human Services. Public Health Service. Clinical practice guideline. Treating tobacco use and dependence: 2008 update. www.ncbi.nlm.nih.gov/books/NBK63952/ (accessed 17 November 2015). ">Fiore 2008</a>). </p> </section> <section id="CD010744-sec-0054"> <h6 class="title">Pharmacological treatments</h6> <p>Placebo‐controlled trials included the investigation of nicotine replacement therapy (NRT) sublingual tablet (<a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>), bupropion (<a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>), nortriptyline (<a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>), and varenicline (<a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>). Three trials compared different pharmacotherapies: bupropion versus NRT patch (<a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a>), NRT versus NRT with bupropion (<a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>), and bupropion versus nortriptyline (<a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>). This last study was the only study using a double‐dummy design when investigating bupropion and nortriptyline against placebo (<a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>). In contrast with the other studies, the use of pharmacotherapy in <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> was not mandatory and not provided for free, which resulted in only a few people using NRT or bupropion. All pharmacological treatments were accompanied by high‐intensity behavioural treatment. <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a> was the only study with a factorial design, as a result of which the behavioural component in the pharmacological comparison was a mix of high‐ and low‐intensity behavioural treatment. </p> </section> </section> <section id="CD010744-sec-0055"> <h5 class="title">Outcomes</h5> <p>Our primary outcome was continuous or prolonged abstinence over a period of six months or longer. Ten studies reported continuous, sustained, or prolonged abstinence. However, the definitions of abstinence used by the studies were diverse and sometimes vague, and did not always match our definition. Furthermore, most of these studies reported abstinence data after an initial grace period. We therefore clustered continuous, sustained, and prolonged abstinence data, which we categorised under the outcome 'prolonged abstinence'. Of the 10 studies reporting prolonged abstinence data, six studies reported six months' and seven studies reported 12 months' prolonged abstinence data. Few studies reported both six and 12 months' abstinence data. Furthermore, <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> reported nine months' and <a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a> reported two‐ to five‐year prolonged abstinence data of the Lung Health Study (LHS). In addition, <a href="./references#CD010744-bbs2-0092" title="AnthonisenNR , ConnettJE , MurrayRP . Smoking and lung function of lung health study participants after 11 years. American Journal of Respiratory and Critical Care Medicine2002;166(5):675‐9. ">Anthonisen 2002</a> reported prolonged abstinence 11 years after the start of the LHS. </p> <p>Our secondary outcome was point prevalence abstinence over a period of six months or longer. Eleven of the 16 included studies reported this outcome. Nine studies reported six months' and eight studies reported 12 months' point prevalence abstinence data. A few studies reported both six and 12 months' abstinence data. Furthermore, <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> reported nine months' and <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a> reported three‐year point prevalence abstinence data. <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a> described abstinence data as being continuous, however their definition of continuous abstinence was vague and corresponded with a mix of prolonged and point prevalence abstinence. In addition, all data except from the six months' follow‐up data were more consistent with point prevalence abstinence data, as the number of abstinent participants increased over time. We therefore categorised the six months' follow‐up data as prolonged abstinence data and the outcome data from six months onwards as point prevalence abstinence data. </p> <p>All abstinence data were biochemically validated, however <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a> only measured exhaled carbon monoxide (CO) levels in self reported non‐smokers, and <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a> only measured CO in a random sample of self reported non‐smokers. <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a> reported that the CO levels of the self reported non‐smokers confirmed their abstinence, and <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a> reported that of the 35 tested, 33 had a CO level of less than 8 ppm, confirming that most of them were indeed abstinent. Eleven studies used exhaled CO measurement techniques, three studies measured cotinine levels in saliva, and three studies measured cotinine in urine. <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a> was an exception, as this study measured the CO level in blood samples. Cutoff levels varied: ≤ 8 to ≤ 10 ppm of CO in exhaled air, ≤ 10 to ≤ 20 ng/mL cotinine in saliva, and ≤ 50 to ≤ 60 ng/mL cotinine in urine. </p> </section> </section> <section id="CD010744-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We excluded 59 of the potentially eligible studies: 10 studies were not randomised controlled trials, 36 studies did not include smokers with COPD, 11 studies were not studying smoking cessation interventions, and two did not report outcome data. These studies are listed with their reasons for exclusion in the <a href="./references#CD010744-sec-0098" title="">Characteristics of excluded studies</a> table. </p> <section id="CD010744-sec-0057"> <h5 class="title">Ongoing studies</h5> <p>We searched the clinical trial registers for ongoing studies and identified two potentially interesting studies that complied with the inclusion criteria for this review (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>). One of the studies compares varenicline plus behavioural treatment with placebo plus behavioural treatment (<a href="./references#CD010744-bbs2-0090" title="NCT01694732 . Efficacy of varenicline on smoking cessation at the acute phase of an exacerbation of chronic obstructive pulmonary disease (SAVE). clinicaltrials.gov/ct2/show/NCT01694732 (Accessed 22 July 2016). ">NCT01694732</a>). The estimated completion date of this study is November 2016. The other study compares behavioural treatment plus NRT with a different behavioural treatment plus NRT (<a href="./references#CD010744-bbs2-0091" title="NCT02148445 . Smoking Cessation Versus Long‐term Nicotine Replacement Among High‐risk Smokers. clinicaltrials.gov/ct2/show/NCT02148445 (Accessed 22 July 2016). ">NCT02148445</a>). The estimated completion date of this study is September 2016. More information about these studies is summarised in the <a href="./references#CD010744-sec-0099" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> </section> <section id="CD010744-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of each item for all included studies is summarised in <a href="#CD010744-fig-0002">Figure 2</a>, and <a href="#CD010744-fig-0003">Figure 3</a> shows the percentages of the different items across all included studies. </p> <div class="figure" id="CD010744-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD010744-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <p>In conclusion, we recommend interpreting the results of six studies with caution, as we expect the risk of bias to have a significant influence on the results (<a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>; <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>). In these studies, there was bias on several important components or bias on one crucial component; contamination bias; or poor adherence to the study protocol. In three studies, four or more components of risk of bias remained unclear and resulted in an overall unclear risk of bias (<a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a>; <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>; <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a>). </p> <section id="CD010744-sec-0059"> <h4 class="title">Allocation</h4> <p>In four of the 16 studies, the random sequence generation method and allocation concealment were not described clearly enough for us to judge possible occurrence of selection bias (<a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>; <a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a>; <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>; <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a>). </p> </section> <section id="CD010744-sec-0060"> <h4 class="title">Blinding</h4> <p>As almost all of the included studies evaluated different behavioural components, it was not possible to blind the participants and personnel for that part of the intervention, resulting in high 'Risk of bias' scores in almost all studies. <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> were the only two pharmacological studies including identical behavioural treatment in all groups and describing the blinding of participants and personnel in detail. Blinding of outcome assessment referred to blinding of self reported or validated abstinence, or both. Only four studies reported any information about blinding. <a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a> and <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a> were the only studies to report on how blinding was performed. <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a> and <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> explicitly reported that they did not blind participants and personnel for the outcome measurement. </p> </section> <section id="CD010744-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Ten studies scored at high risk of bias for incomplete outcome data, due mostly to a high percentage of missing values or the presence of attrition bias, or both. </p> </section> <section id="CD010744-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We detected selective reporting of data in three studies: <a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a> reported different outcome data in different papers and abstracts, <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a> did not report all prespecified outcomes, and <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> did not mention their randomised controlled trial (RCT) being a three‐armed RCT and only reported data from two arms in one of the publications. </p> </section> <section id="CD010744-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Finally, we observed other potentially important forms of bias: adherence to study protocols for participants and personnel was not described in 11 of the studies; was found poor in three studies (<a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>; <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>); and was reported to be satisfactory in only two studies (<a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a>; <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>). Furthermore, contamination bias might have occurred in two studies (<a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>). In <a href="#CD010744-fig-0002">Figure 2</a> the final column shows the combined score for these sources of bias, per study. </p> </section> </section> <section id="CD010744-sec-0064"> <h3 class="title" id="CD010744-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD010744-tbl-0001"><b>Summary of findings for the main comparison</b> Behavioural treatment compared to no treatment or usual care in smokers with COPD</a>; <a href="./full#CD010744-tbl-0002"><b>Summary of findings 2</b> One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD</a>; <a href="./full#CD010744-tbl-0003"><b>Summary of findings 3</b> Pharmacological treatment compared to placebo in smokers with COPD</a>; <a href="./full#CD010744-tbl-0004"><b>Summary of findings 4</b> Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD</a>; <a href="./full#CD010744-tbl-0005"><b>Summary of findings 5</b> Combination interventions compared to different (combination) interventions or usual care for smokers with COPD</a> </p> <p>Outcome data from the included studies was based on complete‐case, intention‐to‐treat (ITT), and modified ITT principles. To increase consistency across study outcome data, we performed an ITT analysis on outcome data from all studies. In the following comparisons we only described subgroup analyses when a meta‐analysis was performed. </p> <section id="CD010744-sec-0065"> <h4 class="title">Comparison 1: Behavioural treatment versus no treatment or usual care</h4> <p>Two studies compared a behavioural treatment with usual care (<a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a>; <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>). The content of the behavioural treatments varied widely, and the studies showed too much statistical heterogeneity for pooling to make sense. <a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a> compared an intervention group in which the doctors used the term "smoker's lung" with a group receiving usual care by using the concept "chronic bronchitis". Only 12 months' point prevalence data were available for this study. In the "smoker's lung" group, 32% (8/25) quit smoking, and in the "chronic bronchitis" group, 16% (5/31) quit smoking (risk ratio (RR) 1.98, 95% confidence interval (CI) 0.74 to 5.31; risk difference (RD) 0.16, 95% CI ‐0.07 to 0.38) (<a href="./references#CD010744-fig-0005" title="">Analysis 1.2</a>). In <a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>, a cluster design was used, and the behavioural‐treatment group received a high‐intensity treatment: the participants were provided written material and individual counselling in the practice and during home visits, and they participated in group meetings. The content and number of usual‐care services were not standardised. Outcome data of this study were difficult to classify according to our definitions. As previously described, we included follow‐up data at six months' follow‐up as prolonged abstinence data and data from six months onwards as point prevalence abstinence data. The prolonged abstinence rate at six months was 4.4% (79/1814) in the behavioural‐treatment group, versus 0.2% (3/1748) in the usual‐care group. The RR was 25.38 (95% CI 8.03 to 80.22) and the RD was 0.04 (95% CI 0.03 to 0.05) (<a href="./references#CD010744-fig-0004" title="">Analysis 1.1</a>). All point prevalence abstinence rates at follow‐up from 12 to 48 months showed a positive effect of the behavioural‐treatment group on abstinence rates. At 48 months, the point prevalence abstinence rate was 33.6% (610/1814) in the behavioural‐treatment group compared with 3.6% (63/1748) in the usual‐care group, with a RR of 9.33 (95% CI 7.26 to 11.99) and a RD of 0.30 (95% CI 0.28 to 0.32) (<a href="./references#CD010744-fig-0005" title="">Analysis 1.2</a>). However, these effects may be overestimated, as the authors did not control for the cluster design of the RCT in their analysis. </p> </section> <section id="CD010744-sec-0066"> <h4 class="title">Comparison 2: One form of behavioural treatment versus a different form of behavioural treatment </h4> <p>Six studies compared two different behavioural treatments (<a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a>; <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>; <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>; <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a>; <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>; <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>). The content of the behavioural treatments varied widely, and the studies showed too much statistical heterogeneity for pooling to make sense. </p> <p><a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a> and <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a> compared a high‐intensity behavioural treatment with a low‐intensity behavioural treatment. In <a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a>, participants received individual counselling, self help material, and telephone follow‐up calls. This behavioural‐treatment group was compared with a low‐intensity behavioural treatment that only provided simple advice to the participants. The six months' prolonged abstinence in the group with high‐intensity counselling was 40% (17/42) compared with 19% (8/43) in the group receiving simple advice. The RR was 2.18 (95% CI 1.05 to 4.49) and the RD was 0.22 (95% CI 0.03 to 0.41) (<a href="./references#CD010744-fig-0006" title="">Analysis 2.1</a>). Point prevalence data of this study were not reported. <a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a> only examined point prevalence abstinence at six months' follow‐up. Rates for abstinence were 27% (10/37) in the group receiving high‐intensity counselling compared with 16.2% (6/37) in the group receiving simple advice (RR 1.67, 95% CI 0.68 to 4.11; RD 0.11, 95% CI ‐0.08 to 0.29) (<a href="./references#CD010744-fig-0007" title="">Analysis 2.2</a>). </p> <p><a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a>, <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>, <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>, and <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> compared a high‐intensity behavioural treatment with a different high‐intensity behavioural treatment. <a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a> compared three different behavioural‐treatment groups. All groups received individual counselling and written material. They differed in the way the participants received lottery tickets for abstinence. Payment of lottery tickets according to abstinence occurred in two groups: one group received payment for self reported abstinence, the other group for CO‐validated abstinence. The third group received lottery tickets when their "buddy" in the other group also received lottery tickets; this was not linked with their smoking status. The authors stated that the three groups did not differ in six months' point prevalence abstinence rates, but there were no data available per group. <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a> compared individual and telephone counselling with confrontation with spirometry, with individual and telephone counselling without confrontation with spirometry. The prolonged abstinence at 12 months' follow‐up in the group with confrontation with spirometry was 11% (13/116) compared with 12% (13/112) in the group without confrontation with spirometry. The RR was 0.97 (95% CI 0.47 to 1.99) and the RD was ‐0.00 (95% CI ‐0.09 to 0.08) (<a href="./references#CD010744-fig-0006" title="">Analysis 2.1</a>). This study reported no point prevalence data. In <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>, the participants in one behavioural‐treatment group received high‐intensity individual counselling and proactive telephone counselling. This group was compared with less intensive ‐ but still high‐intensity according to our definition ‐ individual counselling and proactive telephone counselling. As <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a> was a study with factorial design, the same number of participants in both groups also received either NRT (sublingual tablet) or placebo. The prolonged abstinence rate at 12 months' follow‐up in the group with high‐intensity counselling was 10% (19/187) compared with 9% (17/183) in the group receiving less high‐intensive counselling. The RR was 1.09 (95% CI 0.59 to 2.04) and the RD was 0.01 (95% CI ‐0.05 to 0.07) (<a href="./references#CD010744-fig-0006" title="">Analysis 2.1</a>). The 12 months' point prevalence abstinence rate was 16% (29/187) in the high‐intensity counselling group and 11% (21/183) in the less high‐intensive counselling group (RR 1.35, 95% CI 0.80 to 2.28; and RD 0.04, 95% CI ‐0.86 to 0.94) (<a href="./references#CD010744-fig-0007" title="">Analysis 2.2</a>). <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> compared individual counselling and group counselling. Both groups were also offered the opportunity to use NRT patches. In both groups none of the participants became prolonged abstinent at 12 months (<a href="./references#CD010744-fig-0006" title="">Analysis 2.1</a>). Point prevalence abstinences rates were 0% (0/27) in the individual‐counselling group and 10% (3/29) in the group‐counselling group (RR 0.15, 95% CI 0.01 to 2.83; and RD ‐0.10, 95% CI ‐0.23 to 0.02) (<a href="./references#CD010744-fig-0007" title="">Analysis 2.2</a>). </p> </section> <section id="CD010744-sec-0067"> <h4 class="title">Comparison 3: Pharmacological treatment versus placebo</h4> <p>Four studies compared the following pharmacotherapy with placebo: NRT sublingual tablet (<a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>), bupropion (<a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>), nortriptyline (<a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>), and varenicline (<a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>). All studies except <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> reported both prolonged and point prevalence abstinence data. Primary and secondary outcome data of the individual studies are presented in data and analyses table 3 (<a href="./references#CD010744-fig-0008" title="">Analysis 3.1</a>; <a href="./references#CD010744-fig-0009" title="">Analysis 3.2</a>; <a href="./references#CD010744-fig-0010" title="">Analysis 3.3</a>; <a href="./references#CD010744-fig-0011" title="">Analysis 3.4</a>; <a href="./references#CD010744-fig-0012" title="">Analysis 3.5</a>; <a href="./references#CD010744-fig-0013" title="">Analysis 3.6</a>). All pharmacotherapy groups, except for the nortriptyline group from <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>, showed an increase in the chance of quitting compared with placebo. The prolonged abstinence rates in the pharmacotherapy groups ranged from 14% to 27%. The placebo group quit rates ranged from 5% to 9%. The pooled RR was 2.53 (95% CI 1.83 to 3.50) and the RD 0.10 (95% CI 0.07 to 0.14), with no evidence of heterogeneity (I² = 0%) (<a href="./references#CD010744-fig-0008" title="">Analysis 3.1</a>). The point prevalence abstinence rates in the pharmacotherapy groups ranged from 17% to 26%. The placebo group quit rates ranged from 10% to 16%. The pooled RR was 1.68 (95% CI 1.32 to 2.15) and the RD 0.09 (95% CI 0.05 to 0.13), with no evidence of heterogeneity (I² = 0%) (<a href="./references#CD010744-fig-0011" title="">Analysis 3.4</a>). In all studies, pharmacotherapy was combined with high‐intensity counselling. </p> <p>All studies except <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a> included participants with mostly mild to moderate COPD. <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> included only participants with mild to moderate COPD. In <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>, 89% had mild to moderate and 11% had severe to very severe COPD, and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> included 94% of mild to moderate severity and 6% of severe to very severe COPD patients. In a subgroup analysis, we distinguished between trials with mostly mild‐moderate COPD, <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a>, <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>, and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>, and a trial with a substantial number of people with severe‐very severe COPD (<a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>). Both subgroups showed almost similar prolonged abstinence rates, with a RR of 2.51 (95% CI 1.74 to 3.62) and a RD of 0.11 (95% CI 0.07 to 0.15) in the group with mild‐moderate COPD, and a RR of 2.60 (95% CI 1.29 to 5.24) and a RD of 0.09 (95% CI 0.03 to 0.15) in the study with a substantial number of people with severe‐very severe COPD (<a href="./references#CD010744-fig-0008" title="">Analysis 3.1</a>). Point prevalence abstinence rates were also comparable between the group with mild‐moderate COPD patients (RR 1.66, 95% CI 1.26 to 2.18; RD 0.10, 95% CI 0.05 to 0.15) and the study with a substantial amount of people with severe‐very severe COPD (RR 1.78, 95% CI 1.04 to 3.05; RD 0.08, 95% CI 0.01 to 0.14) (<a href="./references#CD010744-fig-0011" title="">Analysis 3.4</a>). </p> <p>The four studies in this comparison used different kinds of pharmacotherapy. <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a> used NRT (sublingual), <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> used bupropion, <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> also used nortriptyline, and <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a> used varenicline. As previously mentioned, all pharmacotherapy, except for nortriptyline in the <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> study, had a positive effect on prolonged abstinence compared with placebo (<a href="./references#CD010744-fig-0009" title="">Analysis 3.2</a>); the study using NRT had a RR of 2.60 (95% CI 1.29 to 5.24) and a RD of 0.09 (95% CI 0.03 to 0.15), the two studies using bupropion had a pooled RR of 2.03 (95% CI 1.26 to 3.28) and a RD of 0.09 (95% CI 0.03 to 0.15), the study of nortriptyline had a RR of 2.54 (95% CI 0.87 to 7.44) and a RD of 0.13 (95% CI ‐0.01 to 0.26), and varenicline had a RR of 3.34 (95% CI 1.88 to 5.92) and a RD of 0.13 (95% CI 0.07 to 0.18). The chances of point prevalence abstinence were also higher in the groups receiving pharmacotherapy compared with placebo (<a href="./references#CD010744-fig-0012" title="">Analysis 3.5</a>); the study using NRT had a RR of 1.78 (95% CI 1.04 to 3.05) and a RD of 0.08 (95% CI 0.01 to 0.14), the study using bupropion had a RR of 1.46 (95% CI 0.97 to 2.19) and a RD of 0.07 (95% CI ‐0.00 to 0.15), and the study using varenicline had a RR of 1.83 (95% CI 1.27 to 2.65) and a RD of 0.12 (95% CI 0.05 to 0.19). </p> <p>We carried out a sensitivity analysis excluding the study by <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>, as this study showed a high risk of bias due to poor adherence to the treatment protocols. This did not result in a significant change to the prolonged abstinence rate (RR 2.49, 95% CI 1.77 to 3.50; and RD 0.10, 95% CI 0.06 to 0.13). </p> </section> <section id="CD010744-sec-0068"> <h4 class="title">Comparison 4: Pharmacological treatment versus a different pharmacological treatment</h4> <p>Three studies compared pharmacotherapy with a different kind of pharmacotherapy (<a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>). The comparisons the studies made between pharmacotherapies were too diverse for pooling to make sense. In <a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a> and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>, the pharmacotherapy was combined with high‐intensity behavioural treatment. In <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>, the intensity of the behavioural treatment was dependent on the level of motivation for quitting and varied between low and high. </p> <p><a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a> compared bupropion with NRT patch. Prolonged abstinence rates at 12 months were 16% (5/32) in the bupropion group and 21% (8/38) in the NRT patch group with a RR of 0.74 (95% CI 0.27 to 2.05) and a RD of ‐0.05 (95% CI ‐0.23 to 0.13) (<a href="./references#CD010744-fig-0014" title="">Analysis 4.1</a>). No point prevalence data were available for this study. <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> compared a group in which they recommended NRT with a group in which they recommended NRT and bupropion. Prolonged abstinence data were not available, and 12 months' point prevalence rates were 15% (39/252) in the NRT group and 6% (18/291) in the NRT plus bupropion group (RR 2.50, 95% CI 1.47 to 4.26; RD 0.09, 95% CI 0.04 to 0.15) (<a href="./references#CD010744-fig-0015" title="">Analysis 4.2</a>). However, this is likely to be a misrepresentation, as contamination bias occurred in both groups. <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> compared bupropion with nortriptyline in a study with double‐dummy design. In the group using bupropion, 27% (12/44) were prolonged abstinent at six months versus 21% (11/52) in the group using nortriptyline. The RR was 1.29 (95% CI 0.63 to 2.63) and the RD was 0.06 (95% CI ‐0.11 to 0.23) (<a href="./references#CD010744-fig-0014" title="">Analysis 4.1</a>). This study reported no other abstinence data. </p> </section> <section id="CD010744-sec-0069"> <h4 class="title">Comparison 5: Comparison of different combinations of behavioural and pharmacological treatments </h4> <p>Six studies made comparisons between different kinds of pharmacological and behavioural treatments (<a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a>; <a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a>; <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>; <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a>; <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a>; <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a>). The content of the treatments in the different studies was too diverse for pooling to make sense. The studies had in common that they all used high‐intensity behavioural treatments in their experimental group, except for the behavioural treatment in <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a>, which could be low or high intensive, depending on the motivational stage of the participant. </p> <p>Five studies compared an experimental group with usual care. <a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a> compared two different experimental groups with usual care. As receiving a bronchodilator or a placebo was the only difference between the two experimental groups, we combined them into one experimental group. The participants in this group all received counselling in combination with NRT gum. The participants in the control group received usual care. The prolonged abstinence rate at 12 months' follow‐up in the joined experimental group was 34% (1345/3923) and in the usual‐care group 9% (177/1964) (RR 3.80, 95% CI 3.28 to 4.41; and RD 0.25, 95% CI 0.23 to 0.27). The prolonged abstinence at five years' follow‐up in the joined experimental group was 21% (835/3923) and in the usual‐care group 5% (102/1964) (RR 4.10, 95% CI 3.36 to 5.00; and RD 0.16, 95% CI 0.14 to 0.18) (<a href="./references#CD010744-fig-0016" title="">Analysis 5.1</a>). At 11 years' follow‐up 16% (637/3923) in the joined experimental group and 4% (85/1964) in the usual‐care group had been prolonged abstinent (RR 3.75, 95% CI 3.01 to 4.67; and RD 0.12, 95% CI 0.10 to 0.13). We also combined the two experimental groups in <a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> into one experimental group, as in both intervention groups contamination bias occurred, and the advice to use NRT and/or bupropion was given to all participants in both groups. This joined experimental group with a combination of participants using no pharmacotherapy, NRT, and/or bupropion in addition to a behavioural treatment was compared with a usual‐care group. The basis of the behavioural treatment was the minimal intervention strategy and in addition, dependent on the motivational stage, face‐to‐face and/or telephone counselling and written information. Only point prevalence abstinence rates were reported, and at 12 months' follow‐up 7% (39/543) in the joined experimental group and 3% (5/154) in the usual‐care group were abstinent (RR 2.21, 95% CI 0.89 to 5.52; RD 0.04, 95% CI 0.00 to 0.07) (<a href="./references#CD010744-fig-0017" title="">Analysis 5.2</a>). <a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a> compared counselling and nortriptyline with usual care. Prolonged abstinence rates at 12 months were 11% (13/116) in the experimental group and 6% (4/68) in the usual‐care group (RR 1.91, 95% CI 0.65 to 5.61; RD 0.05, 95% CI ‐0.03 to 0.13) (<a href="./references#CD010744-fig-0016" title="">Analysis 5.1</a>). This study did not report point prevalence abstinence rates. In <a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a>, the experimental group consisted of a high‐intensity behavioural treatment with hospitalisation in addition to the recommendation of NRT, which was compared with usual care. No prolonged abstinence rates were reported. The one‐year point prevalence rates were 43% (106/247) in the experimental group and 6% (15/231) in the usual‐care group (RR 6.61, 95% CI 3.97 to 11.01; RD 0.36, 95% CI 0.29 to 0.43). The three‐year point prevalence rates were 30% (73/247) and 7% (20/231), respectively (RR 3.41, 95% CI 2.15 to 5.41; RD 0.21, 95% CI 0.14 to 0.28) (<a href="./references#CD010744-fig-0017" title="">Analysis 5.2</a>). Finally, <a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> had two experimental groups, one with group and one with individual counselling, both plus optional NRT patches, in comparison to brief advice from the doctor. No participants in any of the groups became prolonged abstinent (<a href="./references#CD010744-fig-0016" title="">Analysis 5.1</a>). Point prevalence abstinence rates at 12 months were 0% (0/27) in the individual‐counselling group, 10% (3/29) in the group‐counselling group, and 3% (3/35) in the brief‐advice group (individual counselling plus optional NRT compared with brief advice (RR 0.43, 95% CI 0.02 to 10.12; RD ‐0.03, 95% CI ‐0.11 to 0.05), group counselling plus optional NRT compared with brief advice (RR 3.62, 95% CI 0.40 to 32.97; RD 0.07, 95% CI ‐0.05 to 0.20)) (<a href="./references#CD010744-fig-0017" title="">Analysis 5.2</a>). </p> <p>One study compared high‐intensity counselling plus bupropion with low‐ or high‐intensity counselling, depending on motivational stage, without pharmacotherapy (<a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a>). At 12 months 17% (20/117) of the participants in the counselling plus bupropion group were prolonged abstinent versus 8% (9/117) in the control group (RR 2.22, 95% CI 1.06 to 4.68; RD 0.09, 95% CI 0.01 to 0.18) (<a href="./references#CD010744-fig-0016" title="">Analysis 5.1</a>). Point prevalence abstinence rates at 12 months were 21% (24/117) in the counselling plus bupropion group and 13% (15/117) in the control group (RR 1.60, 95% CI 0.89 to 2.89; RD 0.08, 95% CI ‐0.05 to 0.20) (<a href="./references#CD010744-fig-0017" title="">Analysis 5.2</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010744-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010744-sec-0070">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010744-sec-0131">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010744-sec-0070"></div> <section id="CD010744-sec-0071"> <h3 class="title" id="CD010744-sec-0071">Summary of main results</h3> <p>We reviewed the results of 16 RCTs (including a total of 13123 participants) evaluating the effectiveness of behavioural or pharmacological smoking cessation interventions, or both, in smokers with COPD. We found 11 additional studies in this update of the review (<a href="./references#CD010744-bbs2-0137" title="van derMeerRM , WagenaEJ , OsteloRW , JacobsJE , vanSchayckCP . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2003, Issue 8. [DOI: 10.1002/14651858.CD002999; PUBMED: 12804448] ">van der Meer 2003</a>). The 'Summary of findings' tables 1 to 5 show the results of the main outcomes. </p> <p>There was evidence from one study that high‐intensity behavioural treatment increased abstinence rates when compared with usual care (<a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a>). However, we rated the quality of this study as moderate as we were unclear of the risk of bias due to lack of information (<a href="./full#CD010744-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>One study at low risk of bias showed higher abstinence rates for high‐intensity behavioural treatment over low‐intensity behavioural treatment (<a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a>). Other studies that compared high‐intensity behavioural treatment with another high‐intensity behavioural treatment were too diverse to formulate univocal results (<a href="./full#CD010744-tbl-0002">summary of findings Table 2</a>). </p> <p>We pooled studies comparing pharmacotherapy with placebo and found high‐quality evidence that, in smokers with COPD, pharmacotherapy plus high‐intensity behavioural treatment was effective in increasing quit rates (RR 2.53, 95% CI 1.83 to 3.50) compared with placebo plus high‐intensity behavioural treatment (<a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a>; <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>; <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>; <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>). Among individual studies of pharmacotherapy, nortriptyline did not significantly increase the quit rate (<a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>), whereas nicotine sublingual tablet, in <a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a>, and varenicline, in <a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a>, did. Pooled results of two studies on bupropion, <a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> and <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>, also showed a positive effect of bupropion compared with placebo (<a href="./full#CD010744-tbl-0003">summary of findings Table 3</a>). </p> <p>When comparing different kinds of pharmacological treatments, bupropion did not seem to be more effective than nortriptyline, in <a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a>, or nicotine patch, in <a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a>. However, these studies were not pooled and therefore not rated for quality, but had an overall high and unclear risk of bias, respectively (<a href="./full#CD010744-tbl-0004">summary of findings Table 4</a>). </p> <p>Finally, we compared different combinations of behavioural and pharmacological treatments. These studies were not pooled and therefore not rated for quality. In a study at low risk of bias, high‐intensity behavioural treatment plus nicotine gum increased abstinence rates when compared with usual care (<a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a>). Furthermore, in a study at low risk of bias, high‐intensity behavioural treatment plus bupropion was superior to low‐ or high‐intensity behavioural treatment, depending on motivational stage, without pharmacotherapy (<a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a>). Also, high‐intensity behavioural treatment with hospitalisation plus recommendation of any NRT increased the chance of quitting compared with usual care (<a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a>). However, this last study had a high risk of bias (<a href="./full#CD010744-tbl-0005">summary of findings Table 5</a>). </p> <p>The included studies reported a wide variety of outcome measures, and different studies used different definitions for the same outcome measure. Some studies used point prevalence as the outcome measure, while other studies used continuous abstinence, and some used both. According to <a href="./references#CD010744-bbs2-0131" title="VelicerWF , ProchaskaJO , RossiJS , SnowMG . Assessing outcome in smoking cessation studies. Psychological Bulletin1992;111(1):23‐41. ">Velicer 1992</a>, the use of a combination of outcome measurements is often most appropriate in studies assessing the effects of a smoking cessation intervention. </p> <p>Moreover, in different studies time points to assess the main outcome varied between six months and five years. The 'gold standard' for long‐term follow‐up is six or 12 months (<a href="./references#CD010744-bbs2-0104" title="HatsukamiDK , MooneyME . Pharmacological and behavioral strategies for smoking cessation. Journal of Clinical Psychology in Medical Settings1999;6:11‐38. ">Hatsukami 1999</a>). Most relapses occur early in a quit attempt, and then persist. A measure taken at six months would certainly capture the majority of those relapse events, and 12 months' follow‐up would be even better (<a href="./references#CD010744-bbs2-0134" title="WestR , HajekP , SteadL , StapletonJ . Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction2005;100(3):299‐303. [PUBMED: 15733243] ">West 2005</a>). </p> <p>Also, six out of 16 studies had an overall high risk of bias, and three studies had an unclear risk of bias. This interfered with a clear and concise interpretation of the results. The most striking form of bias was the high proportion of missing data in 10 of the studies. Moreover, blinding was not possible in the behavioural interventions, resulting in a high risk of bias score in almost all of the included studies. </p> <p>Finally, neither the exact content of the behavioural interventions nor that of usual care was always clearly described. This hampered the interpretation and implication of the results. </p> </section> <section id="CD010744-sec-0072"> <h3 class="title" id="CD010744-sec-0072">Overall completeness and applicability of evidence</h3> <p>We are confident that our rigorous search strategy ensured that we have identified the key research to inform this review. The studies in this review were conducted in different countries, which resulted in an international perspective of the results by comparing countries with cultural and economic differences. However, the trials on the same pharmacological intervention in smokers with COPD are limited to single studies only, except for two studies on bupropion. Also, the trials on behavioural interventions are very heterogeneous, and even though we categorised them into high‐ and low‐intensity interventions according to the literature, this still hampers drawing univocal conclusions. Furthermore, the completeness of the evidence was restricted to smoking cessation outcomes and did not include clinical outcomes, such as FEV1. </p> </section> <section id="CD010744-sec-0073"> <h3 class="title" id="CD010744-sec-0073">Quality of the evidence</h3> <p>In the 'Summary of findings' tables the quality of the evidence in the different comparisons is illustrated using the GRADE approach. One study was of low quality, two studies and one pool of studies were of moderate quality, and two studies and one pool of studies were of high quality. In the meta‐analysis, four studies, with a total of 1,429 participants, measured the effect of a pharmacological treatment plus behavioural treatment versus a placebo treatment plus behavioural treatment and showed strong and high‐quality evidence in favour of pharmacological treatment plus behavioural treatment for smoking cessation in smokers with COPD. </p> </section> <section id="CD010744-sec-0074"> <h3 class="title" id="CD010744-sec-0074">Potential biases in the review process</h3> <p>We undertook actions in order to decrease the chance of bias; to ensure that we included all relevant studies, we searched all relevant databases without major restrictions; in addition to the electronic search, we searched for planned, ongoing, and unpublished trials; we checked the reference lists of all included studies and of other systematic reviews in relevant topic areas and searched for errata or retractions from eligible trials; to decrease inter‐rater variability, two review authors independently selected studies for inclusion; these review authors also independently extracted study characteristics from included studies and independently assessed the risk of bias for each study; and any disagreement was resolved by involving a third review author. </p> <p>We used an intensity classification system for the different behavioural interventions. We distinguished high‐ from low‐intensity behavioural treatment. This classification was based on existing criteria from the literature (<a href="./references#CD010744-bbs2-0098" title="US Department of Health and Human Services. Public Health Service. Clinical practice guideline. Treating tobacco use and dependence: 2008 update. www.ncbi.nlm.nih.gov/books/NBK63952/ (accessed 17 November 2015). ">Fiore 2008</a>). However, not all included studies used these criteria, and we had to reclassify some behavioural treatments, which might have introduced bias. Two review authors independently reclassified the behavioural interventions, resolving any disagreements by involving a third review author. </p> </section> <section id="CD010744-sec-0075"> <h3 class="title" id="CD010744-sec-0075">Agreements and disagreements with other studies or reviews</h3> <p>There is evidence that in the general smoking population NRT, bupropion, nortriptyline, varenicline, and cytisine are effective pharmacotherapies for smoking cessation. Varenicline has been shown to be superior to single forms of NRT and bupropion, but not to combination NRT (<a href="./references#CD010744-bbs2-0095" title="CahillK , StevensS , PereraR , LancasterT . Pharmacological interventions for smoking cessation: an overview and network meta‐analysis. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD009329.pub2; PUBMED: 23728690] ">Cahill 2013</a>). Also, adding behavioural treatment to the use of pharmacological treatment shows a small but important effect in increasing the chances of quitting (<a href="./references#CD010744-bbs2-0122" title="SteadLF , KoilpillaiP , LancasterT . Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD009670.pub3; PUBMED: 26457723] ">Stead 2015</a>). </p> <p>In smokers with COPD, international guidelines recommend smoking cessation interventions that are similar to interventions for smokers without COPD (<a href="./references#CD010744-bbs2-0116" title="National Institute for Health and Clinical Excellence. NICE guidelines: Stop smoking service. NICE guidelines [PH10]. www.nice.org.uk/guidance/ph10/chapter/introduction (accessed 17 November 2015). ">NICE 2008</a>; <a href="./references#CD010744-bbs2-0133" title="WestR , McNeillA , RawM . Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax2000;55(12):987‐99. [PUBMED: 11083883] ">West 2000</a>). However, the literature suggests that smokers with COPD have specific characteristics that reduce their chance of successful quitting compared with other smokers (<a href="./references#CD010744-bbs2-0110" title="Jimenez‐RuizCA , MasaF , MiravitllesM , GabrielR , ViejoJL , VillasanteC , et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest2001;119(5):1365‐70. ">Jimenez‐Ruiz 2001</a>; <a href="./references#CD010744-bbs2-0111" title="Jimenez‐RuizCA , AndreasS , LewisKE , TonnesenP , vanSchayckCP , HajekP , et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. European Respiratory Journal2015;46(1):61‐79. [PUBMED: 25882805] ">Jimenez‐Ruiz 2015</a>; <a href="./references#CD010744-bbs2-0121" title="ShahabL , JarvisMJ , BrittonJ , WestR . Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax2006;61(12):1043‐7. ">Shahab 2006</a>; <a href="./references#CD010744-bbs2-0124" title="TashkinDP , MurrayRP . Smoking cessation in chronic obstructive pulmonary disease. Respiratory Medicine2009;103(7):963‐74. [PUBMED: 19285850] ">Tashkin 2009</a>; <a href="./references#CD010744-bbs2-0130" title="vanEerdEA , vanRossemCR , SpigtMG , WesselingG , vanSchayckOC , KotzD . Do we need tailored smoking cessation interventions for smokers with COPD? A comparative study of smokers with and without COPD regarding factors associated with tobacco‐smoking. Respiration2015 (published online); Vol. 90, issue 3:211‐9. ">van Eerd 2015</a>). Currently, systematic reviews on smoking cessation interventions for smokers with COPD do not show differences compared to the general smoking population. Most of the existing reviews, including the previous version of this review (<a href="./references#CD010744-bbs2-0137" title="van derMeerRM , WagenaEJ , OsteloRW , JacobsJE , vanSchayckCP . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2003, Issue 8. [DOI: 10.1002/14651858.CD002999; PUBMED: 12804448] ">van der Meer 2003</a>), included studies which showed that pharmacological treatment plus behavioural treatment is more effective than each strategy separately (<a href="./references#CD010744-bbs2-0118" title="Pires‐YfantoudaR , AbsalomG , ClemensF . Smoking cessation interventions for COPD: a review of the literature. Respiratory Care2013;58(11):1955‐62. [PUBMED: 23431304] ">Pires‐Yfantouda 2013</a>; <a href="./references#CD010744-bbs2-0123" title="StrassmannR , BauschB , SpaarA , KleijnenJ , BraendliO , PuhanMA . Smoking cessation interventions in COPD: a network meta‐analysis of randomised trials. European Respiratory Journal2009;34(3):634‐40. ">Strassmann 2009</a>; <a href="./references#CD010744-bbs2-0125" title="ThabaneM . Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence‐based analysis. Ontario Health Technology Assessment Series2012;12(4):1‐50. [PUBMED: 23074432] ">Thabane 2012</a>; <a href="./references#CD010744-bbs2-0132" title="WarnierMJ , vanRietEE , RuttenFH , DeBruinML , SachsAP . Smoking cessation strategies in patients with COPD. European Respiratory Journal2013;41(3):727‐34. [PUBMED: 22936706] ">Warnier 2013</a>). This conclusion is endorsed by the results of this review. There is little evidence on the intensity of behavioural treatments and the type of pharmacotherapy used (<a href="./references#CD010744-bbs2-0097" title="Coronini‐CronbergS , HeffernanC , RobinsonM . Effective smoking cessation interventions for COPD patients: a review of the evidence. JRSM short reports2011;2(10):78. [PUBMED: 22046497] ">Coronini‐Cronberg 2011</a>; <a href="./references#CD010744-bbs2-0123" title="StrassmannR , BauschB , SpaarA , KleijnenJ , BraendliO , PuhanMA . Smoking cessation interventions in COPD: a network meta‐analysis of randomised trials. European Respiratory Journal2009;34(3):634‐40. ">Strassmann 2009</a>; <a href="./references#CD010744-bbs2-0125" title="ThabaneM . Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence‐based analysis. Ontario Health Technology Assessment Series2012;12(4):1‐50. [PUBMED: 23074432] ">Thabane 2012</a>; <a href="./references#CD010744-bbs2-0132" title="WarnierMJ , vanRietEE , RuttenFH , DeBruinML , SachsAP . Smoking cessation strategies in patients with COPD. European Respiratory Journal2013;41(3):727‐34. [PUBMED: 22936706] ">Warnier 2013</a>). This review adds that high‐intensity behavioural treatment, according to our classification, seemed to result in higher abstinence rates when compared with low‐intensity behavioural treatment. Furthermore, this review did not add conclusive information on the efficacy of the different pharmacological treatments, as the evidence from these studies had a high and unclear risk of bias. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010744-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram" data-id="CD010744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Behavioural treatment versus no treatment or usual care, Outcome 1 Prolonged abstinence at longest follow‐up by intensity of treatment." data-id="CD010744-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Behavioural treatment versus no treatment or usual care, Outcome 1 Prolonged abstinence at longest follow‐up by intensity of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Behavioural treatment versus no treatment or usual care, Outcome 2 Point prevalence abstinence at longest follow‐up by intensity of treatment." data-id="CD010744-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Behavioural treatment versus no treatment or usual care, Outcome 2 Point prevalence abstinence at longest follow‐up by intensity of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 One form of behavioural treatment versus a different form of behavioural treatment, Outcome 1 Prolonged abstinence at longest follow‐up by intensity of treatment." data-id="CD010744-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 One form of behavioural treatment versus a different form of behavioural treatment, Outcome 1 Prolonged abstinence at longest follow‐up by intensity of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 One form of behavioural treatment versus a different form of behavioural treatment, Outcome 2 Point prevalence abstinence at longest follow‐up by intensity of treatment." data-id="CD010744-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 One form of behavioural treatment versus a different form of behavioural treatment, Outcome 2 Point prevalence abstinence at longest follow‐up by intensity of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pharmacological treatment versus placebo, Outcome 1 Prolonged abstinence at longest follow‐up by severity of COPD." data-id="CD010744-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Pharmacological treatment versus placebo, Outcome 1 Prolonged abstinence at longest follow‐up by severity of COPD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pharmacological treatment versus placebo, Outcome 2 Prolonged abstinence at longest follow‐up by pharmacotherapy." data-id="CD010744-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Pharmacological treatment versus placebo, Outcome 2 Prolonged abstinence at longest follow‐up by pharmacotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pharmacological treatment versus placebo, Outcome 3 Prolonged abstinence at longest follow‐up by length of follow‐up." data-id="CD010744-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Pharmacological treatment versus placebo, Outcome 3 Prolonged abstinence at longest follow‐up by length of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pharmacological treatment versus placebo, Outcome 4 Point prevalence abstinence at longest follow‐up by severity of COPD." data-id="CD010744-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Pharmacological treatment versus placebo, Outcome 4 Point prevalence abstinence at longest follow‐up by severity of COPD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pharmacological treatment versus placebo, Outcome 5 Point prevalence abstinence at longest follow‐up by pharmacotherapy." data-id="CD010744-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Pharmacological treatment versus placebo, Outcome 5 Point prevalence abstinence at longest follow‐up by pharmacotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pharmacological treatment versus placebo, Outcome 6 Point prevalence abstinence at longest follow‐up by length of follow‐up." data-id="CD010744-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Pharmacological treatment versus placebo, Outcome 6 Point prevalence abstinence at longest follow‐up by length of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pharmacological treatment versus a different pharmacological treatment, Outcome 1 Prolonged abstinence at longest follow‐up." data-id="CD010744-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Pharmacological treatment versus a different pharmacological treatment, Outcome 1 Prolonged abstinence at longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Pharmacological treatment versus a different pharmacological treatment, Outcome 2 Point prevalence abstinence at longest follow‐up." data-id="CD010744-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Pharmacological treatment versus a different pharmacological treatment, Outcome 2 Point prevalence abstinence at longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison of different combinations of behavioural and pharmacological treatments, Outcome 1 Prolonged abstinence at longest follow‐up." data-id="CD010744-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Comparison of different combinations of behavioural and pharmacological treatments, Outcome 1 Prolonged abstinence at longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010744-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/urn:x-wiley:14651858:media:CD010744:CD010744-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_t/tCD010744-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison of different combinations of behavioural and pharmacological treatments, Outcome 2 Point prevalence abstinence at longest follow‐up." data-id="CD010744-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Comparison of different combinations of behavioural and pharmacological treatments, Outcome 2 Point prevalence abstinence at longest follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/media/CDSR/CD010744/image_n/nCD010744-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010744-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Behavioural treatment compared to no treatment or usual care in smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Behavioural treatment compared to no treatment or usual care in smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> in‐ and outpatients<br/> <b>Intervention:</b> behavioural treatment<br/> <b>Comparison:</b> no treatment or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No treatment or usual care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Behavioural treatment </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b><br/> (14 to 138) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 25.38 (95% CI 8.03, 80.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3562<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 12 to 48 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3618<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to clinical and statistical heterogeneity, studies were not pooled. Individual RR were 1.98 (95% CI 0.74, 5.31) and RR 9.33 (95% CI 7.26, 11.99). 1 study had a high risk of bias due to a serious risk of contamination bias </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>This study had an unclear risk of bias as several important items were scored unclear, for example random sequence generation and allocation concealment. Downgrade once. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Behavioural treatment compared to no treatment or usual care in smokers with COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010744-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> in‐ and outpatients<br/> <b>Intervention:</b> one form of behavioural treatment<br/> <b>Comparison:</b> a different form of behavioural treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>A different form of behavioural treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>One form of behavioural treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>739<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. Individual RR were 2.18 (1.05, 4.49), RR 0.97 (0.47, 1.99), RR 1.09 (0.59, 2.04), and RR not estimable. 3 of the 4 studies had a low risk of bias. 1 study had a high risk of bias due to poor adherence to the study protocol </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. Individual RR were 1.67 (0.68, 4.11), RR 1.35 (0.80, 2.28), and RR 0.15 (0.01, 2.83). 1 study had a low risk of bias, 1 study had a high risk of bias due to participants' poor adherence to the study protocol, and the remaining study had an unclear risk of bias </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">One form of behavioural treatment compared to a different form of behavioural treatment in smokers with COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010744-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pharmacological treatment compared to placebo in smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment compared to placebo in smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> pharmacological treatment<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pharmacological treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>168 per 1000</b><br/> (136 to 207) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.53 (95% CI 1.83, 3.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1429<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months RR 2.54 (95% CI 0.87, 7.44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; nicotine replacement therapy</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>141 per 1000</b><br/> (70 to 283) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.60 (95% CI 1.29, 5.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up; nicotine replacement therapy</b> <br/> Follow‐up: 12 months RR 1.78 (95% CI 1.04, 3.05) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; bupropion</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b><br/> (110 to 285) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.03 (95% CI 1.26, 3.28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>503<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up; bupropion</b><br/> Follow‐up: 6 months RR 1.46 (95% CI 0.97, 2.19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; varenicline</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (104 to 326) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.34 (95% CI 1.88, 5.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up; varenicline</b><br/> Follow‐up: 12 months RR 1.83 (95% CI 1.27, 2.65) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up; nortriptyline</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b><br/> (72 to 620) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.54 (95% CI 0.87, 7.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No point prevalence data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Three studies had a low risk of bias. One study had a high risk of bias due to poor adherence to the study protocol. No downgrade.<br/> <sup>2</sup>Sensitivity analyses including only those studies judged to be at low risk of bias did not impact the pooled results. No downgrade.<br/> <sup>3</sup>One study had a low risk of bias. One study had a high risk of bias due to poor adherence to the study protocol. Downgrade once.<br/> <sup>4</sup>This study had a high risk of bias due to poor adherence to the study protocol. Downgrade once. </p> <p><sup>5</sup>Point estimate for prolonged abstinence includes no difference. Downgrade once for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Pharmacological treatment compared to placebo in smokers with COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010744-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> outpatients<br/> <b>Intervention:</b> pharmacological treatment<br/> <b>Comparison:</b> a different pharmacological treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>A different pharmacological treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Pharmacological treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. NRT vs bupropion RR 0.74 (95% CI 0.27, 2.05), bupropion vs nortriptyline RR 1.29 (95% CI 0.63, 2.63). 1 study had a high risk of bias due to poor adherence to the study protocol. 1 study had an unclear risk of bias </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>155 per 1000</b><br/> (91 to 264) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.5<br/> (1.47 to 4.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NRT vs NRT plus bupropion</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>NRT:</b> nicotine replacement therapy <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>This study had a high risk of bias due to contamination bias. Downgrade once. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Pharmacological treatment compared to a different pharmacological treatment for smokers with COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010744-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Combination interventions compared to different (combination) interventions or usual care for smokers with COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combination interventions compared to different (combination) interventions or usual care for smokers with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> smokers with COPD<br/> <b>Settings:</b> in‐ and outpatients<br/> <b>Intervention:</b> combination interventions<br/> <b>Comparison:</b> different (combination) interventions or usual care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Different (combination) interventions or usual care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Combination interventions</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Prolonged abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 60 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6431<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling due to clinical and statistical heterogeneity. Individual RR 4.10 (3.36, 5.00), RR 2.22 (1.06, 4.68), RR 1.91 (0.65, 5.61), and RR not estimable. 3 studies had a low risk of bias, 1 study had a high risk of bias due to poor adherence to the study protocol </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Point prevalence abstinence at longest follow‐up</b><br/> Follow‐up: 6 to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1535<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No pooling. Individual RR were 1.60 (0.89, 2.89), RR 2.21 (0.89, 5.52), RR 3.41 (2.15, 5.41), RR 0.43 (0.02, 10.12), and RR 3.62 (0.40, 32.97). 3 studies had a high risk of bias due to contamination bias, poor adherence to the study protocol, or poor validation of outcome. 1 study had a low risk of bias </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>COPD:</b> chronic obstructive pulmonary disease; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Combination interventions compared to different (combination) interventions or usual care for smokers with COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010744-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Country</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Setting (in‐/outpatients)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N completed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention 2</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control 1</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control 2</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0001" title="AnthonisenNR , ConnettJE , KileyJP , AltoseMD , BaileyWC , BuistAS , et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA1994;272(19):1497‐505. [PUBMED: 7966841] BuistAS . The US Lung Health Study. Respirology (Carlton, Vic.)1997;2(4):303‐7. [PUBMED: 9525302] ConnettJE , Bjornson‐BensonWM , DanielsK . Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Controlled Clinical Trials1993;14(2 Suppl):38S‐51S. [PUBMED: 8500312] O'HaraP , GrillJ , RigdonMA , ConnettJE , LaugerGA , JohnstonJJ . Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive Medicine1993;22(3):304‐15. [PUBMED: 8327414] ScanlonPD , ConnettJE , WallerLA , AltoseMD , BaileyWC , BuistAS , et al for the Lung Health Study Research Group. Smoking cessation and lung function in mild‐to‐moderate chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2000;161:381–90. ">Anthonisen 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA &amp; US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5887</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0002" title="BrandtCJ , EllegaardH , JoensenM , KallanFV , SorknaesAD , TougaardL . Effect of diagnosis of &quot;smoker's lung&quot;. RYLUNG Group. The Lancet (London, England)1997;349(9047):253. [PUBMED: 9014918] KallanFV , BrandtCJ , EllegaardH , JoensenMB , SorknaesAD , TougaardL . The diagnosis of &quot;smoker's lung&quot; encourages smoking cessation [Diagnosen &quot;rygerlunger&quot; fremmer rygeophor. RYLUNG‐gruppen]. Ugeskrift for Laeger1997;159(44):6528‐30. [PUBMED: 9411973] ">Brandt 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0003" title="ChenJ , ChenY , ChenP , LiuZ , LuoH , CaiS . Effectiveness of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Experimental and Therapeutic Medicine2014;7(3):716‐20. [PUBMED: 24520273] ">Chen 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0004" title="ChristenhuszL , PieterseM , SeydelE , van derPalenJ . Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Education and Counseling2007;66(2):162‐6. [PUBMED: 17196359] ChristenhuszLC , PrengerR , PieterseME , SeydelER , van derPalenJ . Cost‐effectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine and Tobacco Research2012;14(6):657‐63. [PUBMED: 22180589] ">Christenhusz 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0005" title="CrowleyTJ , MacdonaldMJ , WalterMI . Behavioral anti‐smoking trial in chronic obstructive pulmonary disease patients. Psychopharmacology1995;119(2):193‐204. [PUBMED: 7659767] ">Crowley 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In &amp; out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0006" title="GoreckaD , BednarekM , NowinskiA , PuscinskaE , Goljan‐GeremekA , ZielinskiJ . Effect of treatment for nicotine dependence in patients with COPD [Wyniki leczenia uzaleznienia od nikotyny chorych na przewlekla obturacyjna chorobe pluc]. Pneumonologia I Alergologia Polska2003;71(9‐10):411‐7. [PUBMED: 15052977] ">Gorecka 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0007" title="HilberinkSR , JacobsJE , BottemaBJ , deVriesH , GrolRP . Smoking cessation in patients with COPD in daily general practice (SMOCC): six months' results. Preventive Medicine2005;41(5‐6):822‐7. [PUBMED: 16203030] HilberinkSR , JacobsJE , BretelerMH , deVriesH , GrolRP . General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Education and Counseling2011;83(1):120‐4. [PUBMED: 20430565] ">Hilberink 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>697</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0008" title="KotzD , HuibersMJ , WestRJ , WesselingG , vanSchayckOC . What mediates the effect of confrontational counselling on smoking cessation in smokers with COPD?. Patient Education and Counseling2009;76(1):16‐24. [PUBMED: 19150590] KotzD , VosR , HuibersMJ . Ethical analysis of the justifiability of labelling with COPD for smoking cessation. Journal of Medical Ethics2009;35(9):534‐40. [PUBMED: 19717691] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confrontational counselling for smoking cessation in smokers with previously undiagnosed mild to moderate airflow limitation: study protocol of a randomized controlled trial. BMC Public Health2007;7:332. [PUBMED: 18005415] KotzD , WesselingG , HuibersMJ , vanSchayckOC . Efficacy of confronting smokers with airflow limitation for smoking cessation. European Respiratory Journal2009;33(4):754‐62. [PUBMED: 19129277] ">Kotz 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NOR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NOR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0009" title="LouP , ZhuY , ChenP , ZhangP , YuJ , ZhangN , et al. Supporting smoking cessation in chronic obstructive pulmonary disease with behavioral intervention: a randomized controlled trial. BMC Family Practice2013;14:91. [PUBMED: 23802809] ">Lou 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CN</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3562</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2607</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0010" title="PedersonLL , WanklinJM , LefcoeNM . The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. The International Journal of the Addictions1991;26(1):107‐19. [PUBMED: 2066170] ">Pederson 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0011" title="SundbladBM , LarssonK , NathellL . High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine and Tobacco Research2008;10(5):883‐90. [PUBMED: 18569763] ">Sundblad 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>391</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0012" title="TashkinD , KannerR , BaileyW , BuistS , AndersonP , NidesM , et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double‐blind, placebo‐controlled, randomised trial. The Lancet (London, England)2001;357(9268):1571‐5. [PUBMED: 11377644] ">Tashkin 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>411</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0013" title="LockK , WilsonK , MurphyD , RiescoJA . A cost‐effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy2011;12(17):2613‐26. [PUBMED: 22017336] TashkinDP , RennardS , HaysJT , MaW , LawrenceD , LeeTC . Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest2011;139(3):591‐9. [PUBMED: 20864613] TashkinDP , RennardS , Taylor HaysJ , LawrenceD , MartonJP , LeeTC . Lung function and respiratory symptoms in a 1‐year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine2011;105(11):1682‐90. [PUBMED: 21621992] ">Tashkin 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>US</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>504</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐VAR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0014" title="TonnesenP , MikkelsenK , BremannL . Nurse‐conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest2006;130(2):334‐42. [PUBMED: 16899830] ">Tonnesen 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>370</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>288</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0015" title="VanSchayckCP , KaperJ , WagenaEJ , WoutersEF , SeverensJL . The cost‐effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction2009;104(12):2110‐7. [PUBMED: 19922576] WagenaEJ , KnipschildPG , HuibersMJ , WoutersEF , vanSchayckCP . Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Archives of Internal Medicine2005;165(19):2286‐92. [PUBMED: 16246996] ">Wagena 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐BUP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NOR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010744-bbs2-0016" title="WilsonJS , ElbornJS , FitzsimonsD . 'It's not worth stopping now': why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. Journal of Clinical Nursing2011;20(5‐6):819‐27. [PUBMED: 20738455] WilsonJS , ElbornJS , FitzsimonsD , McCrum‐GardnerE . Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self‐report and bio‐chemical validation. International Journal of Nursing Studies2011;48(7):856‐62. [PUBMED: 21288520] WilsonJS , FitzsimonsD , BradburyI , Stuart ElbornJ . Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. International Journal of Nursing Studies2008;45(4):508‐17. [PUBMED: 17184783] ">Wilson 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Out</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BH &amp; PH‐NRT</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CA: Canada; CN: China; DK: Denmark; IE: Ireland; NL: Netherlands; PL: Poland; SE: Sweden; US: United States </p> <p>BH: behavioural; BUP: bupropion; NA: not applicable; NOR: nortriptyline; NRT: nicotine replacement therapy; PH: pharmacological; UC: usual care; VAR: varenicline </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/full#CD010744-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010744-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Behavioural treatment versus no treatment or usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prolonged abstinence at longest follow‐up by intensity of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 High intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.38 [8.03, 80.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Point prevalence abstinence at longest follow‐up by intensity of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.74, 5.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 High intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.33 [7.26, 11.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Behavioural treatment versus no treatment or usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010744-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">One form of behavioural treatment versus a different form of behavioural treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prolonged abstinence at longest follow‐up by intensity of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 High intensity versus low intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 High intensity versus high intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Point prevalence abstinence at longest follow‐up by intensity of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High intensity versus low intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 High intensity versus high intensity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">One form of behavioural treatment versus a different form of behavioural treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010744-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pharmacological treatment versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prolonged abstinence at longest follow‐up by severity of COPD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.07, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Mild‐moderate COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.07, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Severe‐very severe COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Prolonged abstinence at longest follow‐up by pharmacotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.83, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nicotine replacement therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.6 [1.29, 5.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bupropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.18, 3.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Nortriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [0.61, 10.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Varenicline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.34 [1.88, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Prolonged abstinence at longest follow‐up by length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.93, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.71, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Point prevalence abstinence at longest follow‐up by severity of COPD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.32, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Mild‐moderate COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.26, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Severe‐very severe COPD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.04, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Point prevalence abstinence at longest follow‐up by pharmacotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.32, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nicotine replacement therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.04, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Bupropion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.97, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Varenicline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.27, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Point prevalence abstinence at longest follow‐up by length of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 6 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.55, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 12 months follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.34, 2.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pharmacological treatment versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010744-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pharmacological treatment versus a different pharmacological treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prolonged abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Point prevalence abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.47, 4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pharmacological treatment versus a different pharmacological treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010744-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison of different combinations of behavioural and pharmacological treatments</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prolonged abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Point prevalence abstinence at longest follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison of different combinations of behavioural and pharmacological treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010744.pub2/references#CD010744-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010744.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010744-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010744-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="pl#CD010744-note-0001">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010744\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010744\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010744\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010744\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010744\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010744.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010744.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010744.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010744.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010744.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718178214"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010744.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718178218"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010744.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc9fabb34f3fd',t:'MTc0MDcxODE3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 